Feeds:
Posts
Comments

Breakthrough Procedure in Aortic Valve Repair: VIDEO: How to Perform a Transcaval TAVR Procedure

Reporter: Aviva Lev-Ari, PhD, RN

VIEW VIDEO

https://www.dicardiology.com/videos/video-how-perform-transcaval-tavr-procedure

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how his center performs transcaval transcatheter aortic valve replacement (TAVR) access for patients who have suboptimal abdominal aortic and femoral vascular anatomy. Transcaval access was pioneered at Henry Ford Hospital and involves using femoral vein access and then using a surgical radio frequency cutter to bore a hole from the interior venacava into the aorta to allow the TAVR delivery catheter to path through. 

This procedure was developed to enable more patients to receive TAVR via the preferred femoral access route. Some patients are not candidates for femoral artery access because of calcified lesions and heart atherosclerotic plaque, which narrows the vessel lumen, and makes it difficult to thread catheters through. The transcaval access technique can bypass the restricted arteries or heavy calcified plaques to still enable a minimally invasive procedure without the need for surgery. 

This video was produced in partnership from Henry Ford Hospital.

Related Transcaval TAVR Content:

VIDEO: Transcaval Access in TAVR Procedures — Interview with Adam Greenbaum, M.D.

How to Perform Transcaval TAVR Access

VIDEO: Walk Through of the Henry Ford Hospital Structural Heart Cath Lab

Study Deems Transcaval Valve Replacement Pioneered at Henry Ford Hospital Successful

First Transcaval Aortic Valve Replacement Performed in Europe

Additional articles and videos on Henry Ford Hospital 

Find more structural heart technology content

SOURCE

https://www.dicardiology.com/videos/video-how-perform-transcaval-tavr-procedure

Comparative Study: Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants

Reporter: Aviva Lev- Ari, PhD, RN

Marit J. van Gils, A. H. Ayesha Lavell, Karlijn van der Straten, Brent Appelman, Ilja Bontjer, Meliawati Poniman, Judith A. Burger, Melissa Oomen, Joey H. Bouhuijs, Lonneke A. van Vught, Marleen A. Slim, Michiel Schinkel, Elke Wynberg, Hugo D.G. van Willigen, Marloes Grobben, Khadija Tejjani, Jonne Snitselaar, Tom G. Caniels, Amsterdam UMC COVID-19 S3/HCW study group, Alexander P. J. Vlaar, Maria Prins, Menno D. de Jong, Godelieve J. de Bree, Jonne J. Sikkens, Marije K. Bomers, Rogier W. Sanders doi: https://doi.org/10.1101/2021.09.27.21264163

Abstract

Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. We performed a head-to-head comparison of the ability of sera from individuals vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S) to recognize and neutralize the four SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma and Delta). Four weeks after completing the vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (median titers of 1891 and 3061, respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (median titers of 241 and 119, respectively). VOCs neutralization was reduced in all vaccine groups, with the largest (5.8-fold) reduction in neutralization being observed against the Beta variant. Overall, the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after the final vaccination.

Figure 2:Binding and neutralization titers post-vaccination against VOCs.

(A) Median with interquartile range of binding titers to wild-type and VOCs S proteins represented as mean fluorescence intensity (MFI) of 1:100,000 diluted sera collected four-five weeks after full vaccination for the four vaccination groups. The lower cutoff for binding was set at an MFI of 10 (grey shading). Vaccine groups are indicated by colors with BNT162b2 in green, mRNA-1273 in purple, AZD1222 in orange and Ad26.COV2.S in blue. (B) Median with interquartile range of half-maximal neutralization (ID50) titers of D614G and VOCs pseudoviruses for sera collected after full vaccination for the four vaccination groups. The lower cutoff for neutralization was set at an ID50 of 100 (grey shading). Vaccine groups are indicated by colors with BNT162b2 in green, mRNA-1273 in purple, AZD1222 in orange and Ad26.COV2.S in blue. (C) Median ID50 neutralization of D614G and VOCs plotted against the reported vaccine efficacy against symptomatic infection25,1217. Vaccine groups are indicated by colors with BNT162b2 in green, mRNA-1273 in purple, AZD1222 in orange and Ad26.COV2.S in blue. Circles represent WT data, squares for Alpha, diamond for Beta, nabla triangle for Gamma and delta triangle for Delta. Spearman’s rank correlation coefficient with p value are indicated. The result of the AZD1222 phase 3 trial conducted in South Africa, demonstrating poor (10%) efficacy against Beta variant, is not shown.

SOURCE

 https://doi.org/10.1101/2021.09.27.21264163

A laboratory for the use of AI for drug development has been launched in collaboration with Pfizer, Teva, AstraZeneca, Mark and Amazon

Reporter: Aviva Lev-Ari, PhD, RN

AION Labs unites pharma, technology and funds companies including IBF to invest in startups to integrate developments in cloud computing and artificial intelligence to improve drug development capabilities. An alliance of four leading pharmaceutical companies –  
AION Labs
 , the first innovation lab of its kind in the world and a pioneer in the process of adopting cloud technologies, artificial intelligence and computer science to solve the R&D challenges of the pharma industry, today announces its launch.
AstraZeneca ,  
Mark ,  
Pfizer  and 
Teva  – and two leading companies in the field of high-tech and biotech investments, respectively – AWS ( 
Amazon Web Services Inc ) and the Israeli investment fund IBF ( 
Israel Biotech Fund ) – which joined together to establish groundbreaking ventures Through artificial intelligence and computer science to change the way new therapies are discovered and developed.  “We are excited to launch the new innovation lab in favor of discoveries of drugs and medical devices using groundbreaking computational tools,” said Matti Gil, CEO of AION Labs. We are prepared and ready to make a difference in the process of therapeutic discoveries and their development. 
With a strong pool of talent from Israel and the world, cloud technology and artificial intelligence at the heart of our activities and a significant commitment by the State of Israel, we are ready to contribute to the health and well-being of the human race and promote industry in Israel. 
I thank the partners for the trust, and it is an honor for me to lead such a significant initiative. ” 
In addition, AION Labs has announced a strategic partnership with X  
BioMed  , an independent biomedical research institute operating in Heidelberg, Germany. 
BioMed X has a proven track record in advancing research innovations in the field of biomedicine at the interface between academic research and the pharmaceutical industry. 
BioMed X’s innovation model, based on global mass sourcing and incubators to cultivate the most brilliant talent and ideas, will serve as the R & D engine to drive AION Labs’ enterprise model.

SOURCE

Greylock Partners Announces Unique $500 Million Venture to act as Seed Capital Funding for Earliest Stage Startups

Reporter: Stephen J. Williams, Ph.D.

Greylock Partners CEO Reid Hoffman announces a $500 million fund to help the earliest stage startups find capital.

See video below:

https://www.bloomberg.com/multimedia/api/embed/iframe?id=798828e9-7850-4c83-9348-a35d5fad3e1c

https://www.bloomberg.com/news/videos/2021-09-24/intv-sara-guoh-greylock-partners-video

See transcript from Bloomberg.com

00:00This is a lot of money for seed stage deals which is typicallysmaller. Why do you want to make seed such a priority.

00:09So see it has always been a priority for us. We’ve been activeat this stage for a long time and some of our biggest wins

00:15historically have been incubation and seed. So I think companieslike Workday and Palo Alto Networks and more recently abnormal

00:21and Snorkel. And then this year 70 percent of our investmentsyou must mints or seeds before we announce this fund. And so

00:29when we saw this level of opportunity we also want to make surewe had enough funding to really back entrepreneurs and to

00:36support them through their journey and make sure entrepreneursalso know they have different options at the seed for the type

00:41of partners they work with. Now at the seed stage you’re talkingabout companies in their infancy. How early are you investing. I

00:49mean is this ideas on a napkin stage with a couple ofentrepreneurs that you believe in or is it beyond that.

00:58So there definitely is a whole range. We don’t catch everysingle person. Like the day they left their job. Right. But you

01:04know abnormal was to see it in 2018 when it was a slide deck andtwo co-founders. We backed another company recently and self on

01:12first capital. That was a repeat founder we have history with.Similarly no product yet. Just an idea and an early team. And so

01:20the range of when we do see it really depends on when weencounter companies. We do like to get to know people as early

01:26as possible. And sometimes that’s the right time for us to writethe check. Obviously Greylock is a multi-stage venture venture

01:32capital firm and I think founders might have the question here.You know if you give me the seed funding we’ll follow on and

01:38reserves come out of that same bucket. And what could this meanin terms of a longer term relationship with Greylock. What’s the

01:46answer to that. So the first thing I’d start with is seeds forus our core investments. Right. So many firms look at them as

01:54options to then follow on. We look at seeds as investments we’retrying to make money on. We’re building a relationship for the

02:01long term to begin with. Right. So. So I’d start with that thenI’d say it is a third of our fund. So it is a big piece of our

02:09investing. And and you know there are many instances where wethen follow on and invest even more because our conviction

02:16continues or even grows. But the point of us doing seed is notjust a follow on it’s to make that investment. How big is each

02:24deal. I mean would you say that seed is the new series A.I think I think that.

02:33Well let’s see the market data would tell us that round sizesoverall have increased for the same level of progress. And I

02:41think that makes sense right. And the reason being the markethas become a lot smarter at the attractiveness of early stage

02:48technology opportunities. And so great returns in tech venturecapital over many years mean there’s more capital than ever and

02:57people are savvier about software and Internet companies. ButI’d say there is you know I think kind of the noble creature

03:04doesn’t matter so much. We think of it as being the firstinstitutional partner to go to a set of founders. The world is

03:12changing quickly. I mean we’re still in the middle of apandemic. And who would’ve known that you know working from home

03:16was going to be a thing 18 months ago. What are the trends thatyou are most excited about right now that you’re doubling down

03:22on at the seed stage.Yeah. So we invest across the technology spectrum business

03:30consumer. The one you just mentioned in terms of just the seachange of the pandemic in terms of how we do our work together

03:36as one. I’m really excited about but we’ve been we’ve beeninvesting in let’s say just this. There’s a shortage globally

03:44because the pandemic. But even before of human connection andand intimacy and people look for it online. And so we invest in

03:53companies like Dischord and Common ROOM and Promotion that helppeople connect more online. So that’s when we’ll continue to

04:00invest in. And then of course we’re investing across all of yourusual range of SAS social data A.I. etc. and then spending more

04:10and more time in fintech and crypto in particular. Now what arethe potential problems with seed stage. Is that at a certain

04:16point as the company develops maybe they pivot they change. Overtime they could potentially ultimately compete with another one

04:23of your core portfolio companies. How do you manage that.So it’s a good question but it is also something that doesn’t

04:30only happen at the scene and funnily enough Greylock has been aninvestor in several companies that were like great companies

04:37post pivot right. So like first semester and discord and nextdoor after they decided to be what they are today. And so that

04:46you know I’d start with the premise of our our philosophy isthat the company should do what’s best for the company. And we

04:53know our our philosophy is to be fully behind companies and notto go invest in a bunch of competitors in a sector just because

04:59we like this sector. But if that were to happen you know wewould we would just divide those interests within the firm and

05:06like make sure that there’s no information flow and just addressit in a reasonable way. I’ve talked with many of your partners

05:12over the years about investing in more women. And I’m curioushow you look at it as an opportunity to potentially you know

05:22spread the wealth a little bit across more women entrepreneurspeople of color people who historically haven’t gotten a chance

05:29in Silicon Valley and Silicon Valley hasn’t benefited from theirideas.

05:34OK. So I’d say this is an issue that’s near and dear to myheart. We are working on it. Two of the last three founders I

05:40backed are women. One is the seed stage founder. One of thefounders. I backed at the seed stage is Hispanic. But. But I

05:49would say you know one thing I want to make sure is clear. Likeyou want to back great founders from diverse backgrounds across

05:56the spectrum. And like we wouldn’t like do it more in seedbecause seed isn’t important. Because it is important to us.

06:02Right. It’s just across the portfolio. This is a priority.

From TechStartups

Source: https://techstartups.com/2021/09/22/greylock-partners-raises-500-million-invest-seed-stage-startups/

Greylock Partners raises $500 million to invest in seed-stage startups

Nickie LouisePOSTED ON SEPTEMBER 22, 2021


Greylock Partners has raised $500 million to invest exclusively in seed-stage startups. The announcement comes a year after the firm raised $1 billion for its 16th flagship fund to invest in early- and growth-stage tech startups.

Guo and general partner Saam Motamedi said in an interview the fund is part of an expansion of a $1.1 billion fund, which we reported last year, to $1.6 billion, The Information reported. The funding is among the industry’s largest devoted to seed investments, which often represent a startup’s first outside capital.

The pool of funds will give the 56-year-old venture capital firm the ability to write large checks at “lean-in valuations” and emphasize its commitment to early-stage investing, said general partner Sarah Guo. In a thread post on Twitter, Greylock said, “We at @GreylockVC  are excited to announce we’ve raised $500M dedicated to seed investing. This is the industry’s largest pool of venture capital dedicated to backing founders at day one.”

Press Release from Grelock

More articles on Venture Capital on this Online Open Access Journal Include:

youngStartup Ventures “Where Innovation Meets Capital” – First Round of VC Firms Announced, August 4th – 6th, 2020.

Real Time Coverage @BIOConvention #BIO2019: Dealmakers’ Intentions: 2019 Market Outlook June 5 Philadelphia PA

Podcast Episodes by THE EUROPEAN VC

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Technion students have developed a smart tool for predicting the risk of atrial fibrillation – a heart disorder that can lead to critical situations

Reporter: Aviva Lev-Ari, PhD, RN

Atrial fibrillation risk prediction from the 12-lead electrocardiogram using digital biomarkers and deep representation learning 

Shany BitonSheina GendelmanAntônio H RibeiroGabriela MianaCarla MoreiraAntonio Luiz P RibeiroJoachim A Behar European Heart Journal – Digital Health, ztab071, https://doi.org/10.1093/ehjdh/ztab071 Published: 05 August 2021 Article history

Abstract

Aims

This study aims to assess whether information derived from the raw 12-lead electrocardiogram (ECG) combined with clinical information is predictive of atrial fibrillation (AF) development.Methods and results

We use a subset of the Telehealth Network of Minas Gerais (TNMG) database consisting of patients that had repeated 12-lead ECG measurements between 2010 and 2017 that is 1 130 404 recordings from 415 389 unique patients. Median and interquartile of age for the recordings were 58 (46–69) and 38% of the patients were males. Recordings were assigned to train-validation and test sets in an 80:20% split which was stratified by class, age and gender. A random forest classifier was trained to predict, for a given recording, the risk of AF development within 5 years. We use features obtained from different modalities, namely demographics, clinical information, engineered features, and features from deep representation learning. The best model performance on the test set was obtained for the model combining features from all modalities with an area under the receiver operating characteristic curve (AUROC) = 0.909 against the best single modality model which had an AUROC = 0.839.Conclusion

Our study has important clinical implications for AF management. It is the first study integrating feature engineering, deep learning, and Electronic medical record system (EMR) metadata to create a risk prediction tool for the management of patients at risk of AF. The best model that includes features from all modalities demonstrates that human knowledge in electrophysiology combined with deep learning outperforms any single modality approach. The high performance obtained suggest that structural changes in the 12-lead ECG are associated with existing or impending AF.

Graphical AbstractGraphical Abstract

A look at the experimental environment: digital markers (HRV and MOR), deep learning features (DNN), and clinical data (EMR) are combined in a model training to predict atrial fibrillation

Open in new tab Download slide

Keywords

Atrial fibrillationDeep learningRisk prediction Issue Section: Original Article

SOURCES

https://academic.oup.com/ehjdh/advance-article/doi/10.1093/ehjdh/ztab071/6342413?


The students trained a deep learning system (layered neural network) using more than a million ECG records of more than 400,000 patients, thus creating a mechanism to predict human chances of developing atrial fibrillation over a five-year period. They then combined the deep neural network with information. Clinical on the patient.This model was able to correctly predict the risk of developing atrial fibrillation in 60% of cases, while maintaining a high specificity rate of 95% (i.e. only 5% of the people identified as people at risk did not develop the disease

technion.ac.il/2021/10/תחזית-לב/?fbclid=IwAR3RO_5DFnctI9whAffvznEd3hrchfauy6LXZnglVd12cv1z4cfxkwn98Xk

Tweets and Re-Tweets of Tweets by @pharma_BI@AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

REAL TIME EVENT COVERAGE as PRESS by invitation from 2021 Virtual World Medical Innovation Forum at #WMIF2021 @MGBInnovation:

Aviva Lev-Ari, PhD, RN

Tweet Collection Curator:

Aviva Lev-Ari, PhD, RN

UPDATED Twitter Analytics

May 2021  31 days

TWEET HIGHLIGHTS

Top Tweet earned 611 impressions

@MGBInnovation#WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950@pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included pic.twitter.com/9Q2dWikhNd 1  2

View all Tweet activity View Tweet activity

Top Follower followed by 7,598 people

Ryan Gravatt@gravatt FOLLOWS YOU

Christian, father, husband. Owner @RaconteurMC. Strategist for comms, digital. Former award-winning journalist. Proverbs 3:5-6 View profile

Top mention earned 15 engagements

#COVID#vaccines by @Pfizer, @AstraZeneca are probed in @Europe after reports of #heart#inflammation, rare #nerve#disorderpharmaceuticalintelligence.com/2021/05/14/cov… via @pharma_BI@AVIVA1950 1  3View all Tweet activityView Tweet activity

MAY 2021 SUMMARY

Tweets

213

Tweet impressions

17.6K

Profile visits

861

Mentions

211

New followers

2

These are the Tweets and the Re-Tweets

by Day, 5/21, 5/20, 5/19 for

2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

Real Time coverage: Aviva Lev-Ari, PhD, RN

LPBI Group’s Logo
Aviva Lev-Ari, PhD, RN, Founder, 1.0 LPBI Group and 2.0 LPBI Group

May 21, 2021

TWEETS AND RE-TWEETS for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 21, 2021

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 21, 2021

Tweets Originator for Part 1: Aviva Lev-Ari, PhD, RN

From: Mass General Brigham <innovations@partners.org>
Reply-To: <innovations@partners.org>
Date: Monday, May 24, 2021 at 9:31 AM
To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>
Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets
@mandywoodland Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”   @LeapsByBayer Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham@DrLilitGaribyan Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation   @MPDexpert “imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021  
@AVIVA1950 #WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950
Notable Tweets

 

Disruptive Dozen

2021 World Medical Innovation Forum on

YouTube

https://www.youtube.com/results?search_query=Disruptive+Dozen+2021+World+Medical+Innovation+Forum

Example for a TWEET

Aviva Lev-Ari

@AVIVA1950

·

May 21

@MGBInnovation

#WMIF Best Global event on Gene Cell Therapy covered in real time

@AVIVA1950

@pharma_BI

Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

2

2

Example for a RE-TWEET

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 21

Thanks

@AVIVA1950

for sharing this screen capture of the impressive lineup of #GCT “Disruptive Dozen” panelists at #WMIF2021

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · May 21

@MGBInnovation #WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950 @pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

 PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 21, 2021

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Erwan Bezard, PhD INSERM Research Director, Institute of Neurodegenerative Diseases Cautious on reversal

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Nikola Kojic, PhD CEO and Co-Founder, Oryon Cell Therapies Autologus cell therapy placed focal replacing missing synapses reestablishment of neural circutary

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Bob Carter, MD, PhD Chairman, Department of Neurosurgery, MGH William and Elizabeth Sweet, Professor of Neurosurgery, HMS Neurogeneration REVERSAL or slowing down? 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS efficacy Autologous cell therapy transplantation approach program T cells into dopamine genetating cells greater than Allogeneic cell transplantation 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS Pharmacologic agent in existing cause another disorders locomo-movement related 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas

@pharma_BI

@AVIVA1950

1

3

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT 

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Oleg Nodelman Founder & Managing Partner, EcoR1 Capital Invest in company next round of investment will be IPO 20% discount

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Peter Kolchinsky, PhD Founder and Managing Partner, RA Capital Management Future proof for new comers disruptors  Ex Vivo gene therapy to improve funding products what tool kit belongs to 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

4h

#WMIF2021

@MGBInnovation

Deep Nishar Senior Managing Partner, SoftBank Investment Advisors Young field vs CGT started in the 80s  high payloads is a challenge 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Bob Carter, MD, PhD MGH, HMS cells producing dopamine transplantation fibroblast cells metabolic driven process lower mutation burden  Quercetin inhibition elimination undifferentiated cells graft survival oxygenation increased 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Chairman, Department of Neurosurgery, MGH, Professor of Neurosurgery, HMS Cell therapy for Parkinson to replace dopamine producing cells lost ability to produce dopamine skin cell to become autologous cells reprogramed  

@pharma_BI

@AVIVA1950

#WMIF2021

@MGBInnovation

Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH Off-th-shelf one time treatment becoming cure  Intact tissue in a dish is fragile to maintain metabolism to become like semiconductors

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Ole Isacson, MD, PhD Director, Neuroregeneration Research Institute, McLean Professor, Neurology and Neuroscience, MGH, HMS Opportunities in the next generation of the tactical level Welcome the oprimism and energy level of all

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Erin Kimbrel, PhD Executive Director, Regenerative Medicine, Astellas In the ocular space immunogenecity regulatory communication use gene editing for immunogenecity Cas1 and Cas2 autologous cells

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Nabiha Saklayen, PhD CEO and Co-Founder, Cellino scale production of autologous cells foundry using semiconductor process in building cassettes by optic physicists

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Joe Burns, PhD VP, Head of Biology, Decibel Therapeutics Ear inside the scall compartments and receptors responsible for hearing highly differentiated tall ask to identify cell for anticipated differentiation control by genomics

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH first drug required to establish the process for that innovations design of animal studies not done before 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Meredith Fisher, PhD Partner, Mass General Brigham Innovation Fund Strategies, success what changes are needed in the drug discovery process@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Manufacturing change is not a new clinical trial FDA need to be presented with new rethinking for big innovations Drug pricing cheaper requires systematization

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

Kush Parmar, MD, PhD Managing Partner, 5AM Ventures Responsibility mismatch should be and what is “are”

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

5h

#WMIF2021

@MGBInnovation

David Berry, MD, PhD CEO, Valo Health GP, Flagship Pioneering Bring disruptive frontier platform reliable delivery CGT double knockout disease cure all change efficiency scope human centric vs mice centered right scale acceleration

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

6h

#WMIF2021

@MGBInnovation

Kush Parmar, MD, PhD Managing Partner, 5AM Ventures build it yourself, benefit for patients FIrst Look at MGB shows MEE innovation on inner ear worthy investment  

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

6h

#WMIF2021

@MGBInnovation

Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Frustration with supply chain during the Pandemic, GMC anticipation in advance CGT rapidly prototype rethink and invest proactive investor .edu and Pharma

@pharma_BI

@AVIVA1950

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 21, 2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

The # of US patients with Parkinson’s Disease is expected to double over next 30 years. Penelope Hallett PhD, Co-Director of the Neuroregeneration Research Inst

@McLeanHospital

, presents a #regenerativemedicine approach that could alter that trajectory. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Our “Capital Formation ’21-30 | Investing Modes Driving GCT Technology and Timing” panelists have taken the stage. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

CAR-T therapies have proven remarkably effective. Now,

@MassGenBrigham

researchers including

@MGHCancerCenter

Marcela Maus, MD PhD, are working to expand the reach of this transformative technology. #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #9. Building the Next Wave of CAR-T-cell Therapies #WMIF2021 #GCT #GeneAndCellTherapy #CellTherapy #CarT #DisruptiveDozen

1

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #6. Eyes and Ears: Expanding Gene Therapy’s Reach #WMIF2021 #GCT #GeneAndCellTherapy #GeneTherapy #DisruptiveDozen

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 20

If you’ve missed some First Look sessions, don’t worry! We’ve got you covered. Our First Look On-Demand videos, featuring 18

@MassGenBrigham

investigators giving previews of their #GCT research, are available to view on the #WMIF2021 conference platform. https://worldmedicalinnovation.org/register/

5

7

You Retweeted

REGENXBIO

@REGENXBIO

·

May 19

This morning at 10:20 a.m. ET, our CEO, Ken Mills, will be participating live on the AAV Success Studies virtual panel at the #WMIF2021, hosted by

@MGBInnovation

. Click here to register: https://bit.ly/33tHTti #Genetherapy

Register | World Medical Innovation Forum – Gene and Cell Therapy

Hear from industry-leading experts discuss the advances and future of GCT in health care. May 19-21, 2021; Mass General Brigham. Register!

worldmedicalinnovation.org

2

3

You Retweeted

Brett P. Monia, Ph.D.

@BPMonia

·

May 20

Looking forward to joining

@MGBInnovation

and global colleagues at #WMIF2021. On Thursday, May 20, my colleagues and I will discuss the advantages of RNA-targeted medicines and how they might shape the future of medicine for patients.

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · May 10

Are you part of the @MassGenBrigham network and interested in #GeneAndCellTherapy? Join us at the World Medical Innovation Forum on 5/19-5/21. Register today! https://worldmedicalinnovation.org/register/ #WMIF2021

1

5

You Retweeted

Maria Luiza Gutierrez de Andrade Seixas

@MLGASeixas

·

May 16

Incredible opportunity to get up to speed with the most innovative technologies in medicine ! Gene and cell therapy are revolutionizing healthcare ! #WMIF2021 #MedTwitter

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · May 11

#WMIF2021 is an opportunity for innovators from around the globe to meet, explore, challenge, and reflect on the issues influencing the adoption of novel technologies in #healthcare. Register now to join the conversation: https://worldmedicalinnovation.org/register/

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Currently, the only cure for some common blood disorders is a bone marrow transplant, which can be risky. Now, gene therapies are also in the works, including a CRISPR-based #genetherapy being tested in clinical trials with encouraging early results. #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #2. A Genetic Fix for Two Common Blood Disorders #WMIF2021 #GCT #GeneAndCellTherapy #BloodDisorders #DisruptiveDozen

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Researchers have pinpointed key genes involved in cholesterol and lipid metabolism that represent promising targets for new cholesterol-lowering treatments. #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #1. A New Generation of Cholesterol-Loweing Therapies #WMIF2021 #GCT #GeneAndCellTherapy #DisruptiveDozen

2

1

You Retweeted

Harvard Ophthalmology

@HMSeye

·

May 19

The

@MGBInnovation

#WMIF2021 event kicks of this morning! Congratulations to faculty member and event Co-Chair

@VandenbergheLuk

on putting together such a terrific program. Register: https://bit.ly/3uWYB0E

4

9

You Retweeted

Yulia Grishchuk Lab

@GrishchukL

·

4h

I really enjoyed this remarkable panel #WMIF2021. Thank you Meredith Fisher for moderating and thank you David, Bob and Kush for openly sharing your big picture view

1

4

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

Thank you to our World Medical Innovation Forum Collaborators

@Amplify_Bio

@bostonsci

@CanonUSA

@CatalentPharma

@InterSystems

@nlvcofficial

@onemedical

@ReconStrategy

@SiemensHealth

@thermofisher

@VertexPharma

#WMIF2021

You Retweeted

Tracy Doyle

@doylet

·

5h

Variability, delays, manufacturing as an afterthought make #GCT challenging from an investment POV — need to rethink the ecosystem and drive efficiency, invest in tech innovation says Bob Nelson ARCH Venture Partners

@MGBInnovation

#WMIF2021

1

You Retweeted

Tracy Doyle

@doylet

·

5h

We need to change the scale and scope of how #GCT is advancing from discovery to development — systematization critical. Can’t have thousands of one-off therapies say early-stage investors. Major mis-match between where things are now and what could be.

@MGBInnovation

#WMIF202

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #8. Replacing What’s Lost: Stem Cell Therapies for Diabetes #WMIF2021 #GCT #GeneAndCellTherapy #StemCell #StemCellResearch #Diabetes #DisruptiveDozen

3

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

21h

An overview of our CEO Panel featuring Lisa Deschamps of

@NovartisGene

, Kieran Murphy of

@GEHealthcare

and Christian Rommel PhD, of

@Bayer

#WMIF2021

4

7

You Retweeted

Mass General Brigham

@MassGenBrigham

·

4h

Gene and cell therapies could change the future of medicine for patients w chronic disease or rare/ultra-rare disease – hear how

@MassGenBrigham

is working w the GCT ecosystem to drive new discoveries from bench to bedside #GCT #WMIF2021

5

11

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

That’s a wrap! Thank you to everyone who helped make #WMIF2021 such a success, especially our incredible sponsors:

@NovartisGene

@Bayer

@GEHealthcare

@AstellasUS

@biogen

@FujifilmHealth

and more. Full list: https://worldmedicalinnovation.org/sponsors/

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

Disruptive Dozen: 12 Technologies that Will Reinvent GCT #1. A New Generation of Cholesterol-Loweing Therapies #WMIF2021 #GCT #GeneAndCellTherapy #DisruptiveDozen

5

2

You Retweeted

Natalie Artzi

@NatalieArtzi

·

17h

Today I moderated a panel on Gene and Cell Therapy Delivery, Perfecting the Technology. We highlighted non-viral delivery technologies as key enablers of gene therapy and editing. Learn more: https://lnkd.in/d-Xqzqh #WMIF2021

3

12

You Retweeted

Yulia Grishchuk Lab

@GrishchukL

·

5h

Thank you

@MGBInnovation

and

@LeapsByBayer

for this award! Congratulations to

@BKleinstiver

and all other winners!

@MGH_RI

@CGM_MGH

! #WMIF2021

Quote Tweet

Leaps by Bayer

@LeapsByBayer

 · 6h

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham…

Show this thread

2

5

You Retweeted

Natalie Artzi

@NatalieArtzi

·

17h

An artistic description of an exciting panel I led today, at the World Biomedical Innovation Forum, discussing the future of non-viral delivery systems for gene therapy. #MatthewStanton #LauraSeppLorenzino #DouglasWilliams #SonyaMontgomery #WMIF2021

May 20, 2021

TWEETS AND RE-TWEETS for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 20, 2021

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 20, 2021

Tweets Originator for Part 1: Aviva Lev-Ari, PhD, RN

Example for a TWEET

Aviva Lev-Ari

@AVIVA1950

·

May 21

@MGBInnovation

#WMIF Best Global event on Gene Cell Therapy covered in real time

@AVIVA1950

@pharma_BI

Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

2

2

Example for a RE-TWEET

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 21

Thanks

@AVIVA1950

for sharing this screen capture of the impressive lineup of #GCT “Disruptive Dozen” panelists at #WMIF2021

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · May 21

@MGBInnovation #WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950 @pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 20, 2021

Aviva Lev-Ari

@AVIVA1950

·

2h

#WMIF2021

@MGBInnovation

Bob Brown, PhD CSO, EVP of R&D, Dicerna small molecule vs capacity of nanoparticles to deliver therapeutics quantity for more molecule is much larger CNS delivery most difficult

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Jeannie Lee, MD, PhD Molecular Biologist, MGH Prof Genetics, HMS 200 disease X chromosome unlock for neurological genetic diseases: Rett Syndrome, autism spectrum disorders female model vs male mice model restore own protein

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Suneet Varma Global President of Rare Disease, Pfizer review of protocols and CGT for Hemophilia Pfizer: You can’t buy Time With MIT Pfizer is developing a model for Hemophilia CGT treatment

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Gallia Levy, MD, PhD CMO, Spark Therapeutics Hemophilia CGT is the highest potential for Global access logistics in underdev countries working with NGOs practicality of the Tx Roche reached 120 Counties great to be part of the Roche

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Theresa Heggie CEO, Freeline Therapeutics Safety concerns, high burden of treatment CGT has record of safety and risk/benefit adoption of Tx functional cure CGT is potent Tx relative small quantity of protein needs be delivered 

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Suneet Varma Global President of Rare Disease, Pfizer Gene therapy at Pfizer small, large molecule and CGT – spectrum of choice allowing Hemophilia patients to marry 1/3 internal 1/3 partnership 1/3 acquisitions  review of protocols

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Ron Renaud CEO, Translate Bio What strain of Flu vaccine will come back in the future when people do not use masks. AAV vectors small transcript size fit reach cytoplasm more development coming

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna Flu vaccine knowing the virus variant 45 days for Personalized cancer vaccine one per patient

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna Many years of mRNA pivoting for new diseases, DARPA, nucleic Acids global deployment of a manufacturing unit on site where the need arise Elan Musk funds new directions at Moderna

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna How many mRNA can be put in one vaccine: Dose and tolerance to achieve efficacy and the 

@pharma_BI

@AVIVA1950

1

2

Aviva Lev-Ari

@AVIVA1950

·

9h

#WMIF2021

@MGBInnovation

Lindsey Baden, MD Director, Clinical Research, Division of Infectious Diseases, BWH Associate Professor, HMS In vivo delivery process regulatory for new opportunities for same platform new indication using multi valence vaccines

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Ron Renaud CEO, Translate Bio Platform allowing to swap cargo reusing same nanoparticles address disease beyond Big Pharma options for biotech

@pharma_BI

@AVIVA1950

#WMIF2021

@MGBInnovation

Melissa Moore Chief Scientific Officer, Moderna Many years of mRNA pivoting for new diseases, DARPA, nucleic Acids global deployment of a manufacturing unit on site where the need arise Elan Musk funds new directions at Moderna

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Ron Renaud CEO, Translate Bio 1.6 Billion doses produced rare disease monogenic correct mRNA like CF multiple mutation infection disease and oncology applications

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Kate Bingham, UK Vaccine Taskforce July 2020, AAV vs mRNA delivery across UK local centers administered both types supply and delivery uplift 

@pharma_BI

@AVIVA1950

1

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Melissa Moore CSO, Moderna mRNA vaccine 98% efficacy for Pfizer and Moderna more then 10 years 2015 mRNA was ready (ZIKA, RSV), as the proteine is identify manufacturing temp less of downside in the future ability to store at Ref

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Shunfei Yan, PhD Investment Manager, InnoStar Capital Indication driven: Hymophilia,  Allogogenic efficiency therapies Licensing opportunities 

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Richard Wang, PhD CEO, Fosun Kite Biotechnology Co. Ltd Possibilities to be creative and capitalize the new technologies for new drug Support of the ecosystem by funding new companies Autologous in patients differences cost challenge

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Tian Xu, PhD Vice President, Westlake University ICH Chinese FDA -r regulation similar to the US Difference is the population recruitment, in China patients are active participants Dev of transposome non-viral methods, price

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

10h

#WMIF2021

@MGBInnovation

Alvin Luk, PhD CEO, Neuropath Therapeutics Monogenic rare disease with clear genomic target Increase of 30% in patient enrollment  Regulatory reform approval is 60 days no delay

@pharma_BI

@AVIVA1950

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 20, 2021

You Retweeted

Vertex Pharmaceuticals

@VertexPharma

·

May 19

We’re excited to attend this week’s #WMIF2021 to talk all things cell and genetic therapies. Join our Chief of VCGT Bastiano Sanna tomorrow at 9:50am EDT for a discussion on the promise of cell therapies for type 1 diabetes. Register now! https://bit.ly/3otngYd

2

4

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

8h

John Fish, Board Chair, Brigham Health, Chairman & CEO, Suffolk on the Novartis Main Stage to introduce the “Collaboration is Key: GCT R&D of the Future” fireside chat with Jay Bradner, MD, President, NIBR

@NovartisScience

. #WMIF2021

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

In our next First Look presentation we’ll hear from Xandra Breakefield PhD & Koen Breyne PhD

@MGHNeurology

@MGHNeurosurg

about their work focused on developing non-viral vectors to enhance #genedelivery. #WMIF2021 #GCT #genetherapy

More Topics

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 19

Thomas VanCott, PhD, Chief Technology & Strategy Officer, Catalent Cell & Gene Therapy, says that time, improvements and scaling up in manufacturing will lead to allogeneic cell therapies. He recognizes that upfront costs are high, but will decrease in the long term #WMIF2021

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Ravi Thadhani, CAO

@MassGenBrigham

and Juergen Eckhardt, Head of

@LeapsbyBayer

, are announcing the 2021 Innovation Discovery Grants this afternoon at #WMIF2021.

1

3

You Retweeted

Editas Medicine

@editasmed

·

10h

Today Lisa Michaels, Editas CMO, will participate in the panel “Gene Editing – Achieving Therapeutic Mainstream” at the World Medical Innovation Forum #WMIF2021 in Boston. For those attending, be sure to tune in!

@MassGenBrigham

https://bit.ly/3hx1XTV #geneediting #biotechnology

Gene Editing | Achieving Therapeutic Mainstream – 2021 World Medical Innovation Forum

Gene editing was recognized by the Nobel Committee as “one of gene technology’s sharpest tools, having a revolutionary impact on life sciences.” Introduced in 2011, gene editing is used to modify…

worldmedicalinnovation.org

1

1

7

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

3h

A behind the scenes peek at our “Gene Editing | Achieving Therapeutic Mainstream” moderator & panelists preparing to go live. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

Thank you to the “Common Blood Disorders | Gene Therapy” moderator David Scadden, MD

@ScaddenLab

@harvardstemcell

and panelists Leslie Kean, MD PhD

@DanaFarberNews

, Samarth Kulkarni, PhD

@CRISPRTX

, Nick Leschly

@bluebirdbio

, Mike McCune, MD PhD

@gatesfoundation

. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Kieran Murphy, CEO,

@GEHealthcare

, views GCT as the ultimate precision medicine. AI, machine learning, and data science comprise one of the big disruptive forces that will address misdiagnosis, smooth out workflow, reduce cost and enhance recovery. #WMIF2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

Wrapping up Day 2 of #WMIF2021 with the “Gene Expression | Modulating with Oligonucleotide-Based Therapies” panel.

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Juergen Eckhardt, Head of

@LeapsbyBayer

, announces new Bayer mentoring program for Innovation Discovery Grant winners at #WMIF2021.

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

2h

In our final First Look session of the day, Pierpaolo Peruzzi, MD PhD,

@BWHNeurosurgery

presents “RNA Therapy for Brain Cancer” #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Hear from

@intelliatweets

CSO Laura Sepp-Lorenzino, PhD, in our “GCT Delivery | Perfecting the Technology” panel this afternoon! #WMIF2021

Quote Tweet

Intellia Therapeutics

@intelliatweets

 · 6h

Today, Intellia CSO, @LauraSeppLore will be participating in the World Medical Innovation Forum’s panel on Gene and Cell Therapy Delivery, Perfecting the Technology. #WMIF2021 @MGBInnovation. Click here to learn more: https://worldmedicalinnovation.org

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Natalie Artzi, PhD, Assistant Professor

@BrighamWomens

is back with us this afternoon sharing a First Look at “Versatile Polymer-Based Nanocarriers for Targeted Therapy and Immunomodulation.” #WMIF2021 #GCT #geneandcelltherapy

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

8h

We look forward to hearing from

@ViaCyte

VP of Clinical Development, Manasi Jaiman, during the “Diabetes | Grand Challenge” panel today. #WMIF2021

Quote Tweet

ViaCyte

@ViaCyte

 · 8h

Join us at #WMIF2021 today! Our own Manasi Jaiman, VP, Clinical Development, will participate in the Diabetes: Grand Challenge panel to discuss regenerative medicine approaches for T1D utilizing stem-cell derived islet cell replacement therapy.

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

5h

We’ll see you back here after the break for the “GCT Delivery | Perfecting the Technology” panel, featuring moderator Natalie Artzi, PhD,

@BrighamWomens

and panelists from

@EvOx_Ltd

,

@intelliatweets

,

@generationbio

and

@codiakbio

. #WMIF2021

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Christian Rommel, PhD,EVP, Head, Pharmaceuticals Research & Development,

@Bayer

, discusses how GCT is in the embryonic phase. Bayer is ready to treat its first Parkinson’s patient, and is exploring therapeutic technologies to treat diseases with single gene defects #WMIF2021

1

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

8h

Next up is the #Diabetes | Grand Challenge panel at #WMIF2021 featuring speakers from

@BrighamWomens

@armi_usa

@ViaCyte

@VertexPharma

@Sigilon_Inc

3

5

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

10h

The “Gene Editing | Achieving Therapeutic Mainstream” panel today at 2:55 pm Eastern will discuss the movement of #geneediting technology into the therapeutic mainstream. Join us! #WMIF2021 https://worldmedicalinnovation.org/register/

Quote Tweet

Editas Medicine

@editasmed

 · 10h

Today Lisa Michaels, Editas CMO, will participate in the panel “Gene Editing – Achieving Therapeutic Mainstream” at the World Medical Innovation Forum #WMIF2021 in Boston. For those attending, be sure to tune in! @MassGenBrigham https://bit.ly/3hx1XTV #geneediting #biotechnology

You Retweeted

Atara Bio

@Atarabio

·

2h

Global Head of R&D

@jdupontmd

joined this week’s World Medical Innovation Forum hosted by

@MGBInnovation

to discuss the current state of CAR-T and its future prospects. These conversations are important for the development of potential #CART therapies. #WMIF2021

1

8

You Retweeted

Tracy Doyle

@doylet

·

9h

“We can get to an “n of 1” with mRNA technology says Melissa Moore, PhD, CSO Platform Research,

@moderna_tx

@MGBInnovation

#WMIF2021 #GCT

1

1

You Retweeted

Intellia Therapeutics

@intelliatweets

·

6h

Today, Intellia CSO,

@LauraSeppLore

will be participating in the World Medical Innovation Forum’s panel on Gene and Cell Therapy Delivery, Perfecting the Technology. #WMIF2021

@MGBInnovation

. Click here to learn more: https://worldmedicalinnovation.org

3

4

You Retweeted

TranslateBio

@TranslateBio

·

7h

Graphical representation of this morning’s #mRNA #vaccines panel at

@MGBInnovation

‘s #WMIF2021 — Thanks to the MGB team for facilitating a great discussion!

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 7h

Overview of our #mRNA Vaccines panel today, highlighting improved manufacturing capabilities & potential for #personalizedmedicine. Thank you to Lindsey Baden @bwh_id & panelists Kate Bingham, SV Health Investors, Melissa Moore @moderna_tx and Ron Renaud @TranslateBio #WMIF2021

1

3

You Retweeted

Tracy Doyle

@doylet

·

May 19

18

@MassGenBrigham

investigators are ready to give you an early preview of their #GCT research in the First Look sessions at #WMIF2021. Exciting opportunities to dramatically change how disease is treated!

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

7h

Please welcome Marc Casper, CEO

@thermofisher

to the stage for a Fireside Chat moderated by Erin Harris

@ErinHarris_1

, Editor in Chief

@_CellandGene

“Partnering Across the GCT Spectrum” #WMIF2021 #GCT #geneandcelltherapy

4

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

The “CEO Panel | Anticipating Disruption | Planning for Widespread GCT” panelists have joined the stage. #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

7h

Our “Rare and Ultra Rare Diseases | GCT Breaks Through” panelists on the role of family organizations & patient advocacy groups in moving us forward on the regulatory side – “It’s absolutely essential” #WMIF2021

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Lydia Lynch PhD, Brigham and Women’s Hospital receives an Innovation Discovery Grant for “Generating Superior ‘Killers’ for Adoptive Cell Therapy in Cancer” at #WMIF2021.

@BrighamWomens

@BrighamResearch

2

You Retweeted

Tracy Doyle

@doylet

·

10h

Looking forward to the Diabetes Grand Challenge and how #GCT could help millions of people. Read about what facing this disease and how cell therapies could lessen the burden from Manasi Jaiman, MD, VP, Clinical Development

@ViaCyte

here http://bit.ly/T1Dcelltherapies… #WMIF2021

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 11h

Today is Day 2 of the World Medical Innovation Forum. Which panel you are most excited to see today? Reply and let us know! #WMIF2021 https://worldmedicalinnovation.org/agenda/

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Coming up at 12:05 pm Eastern: “CEO Panel | Anticipating Disruption | Planning for Widespread GCT” featuring panelists from

@NovartisGene

@GEHealthcare

@Bayer

and moderated by

@CNBC

Senior Health and Science Reporter

@megtirrell

#WMIF2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

10h

Join us at #WMIF2021 to hear from Suneet Varma, Global President of Rare Disease

@Pfizer

, during the “Benign Blood Disorders” today at 9:00 am Eastern. https://worldmedicalinnovation.org/register/

Quote Tweet

Pfizer Inc.

@pfizer

 · May 19

Cell and gene therapies hold promising potential for rare disease, blood cancers, and viral diseases. Register for #WMIF21 to hear about our work to pioneer cutting-edge science across our pipeline to advance breakthroughs that change patients’ lives: https://on.pfizer.com/3f3CGzj

2

1

You Retweeted

Pearl Freier

@PearlF

·

9h

Melissa Moore/Moderna said they are working with Merck on developing personalized cancer vaccines, n of 1 #wmif2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Peter Sage PhD, Brigham and Women’s Hospital receives an Innovation Discovery Grant for “Novel Strategies to Enhance Tfr Treatment of Autoimmunity” at #WMIF2021

@BrighamWomens

@BrighamResearch

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Yulia Grishchuk PhD, Massachusetts General Hospital, receives an Innovation Discovery Grant for “AAV-Based Gene Replacement Therapy Improves Targeting and Clinical Outcomes in a Childhood CNS Disorder” at #WMIF2021

@MassGeneralNews

@MGH_RI

@CGM_MGH

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Jinjun Shi, PhD, Brigham and Women’s Hospital, receives an Innovation Discovery Grant for “Long-Lasting mRNA Therapy for Genetic Disorders” at #WMIF2021

@BrighamWomens

@BrighamResearch

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

9h

Final thoughts from “Benign Blood Disorders” panelists on academic/industry collaboration — the pace of #innovation is incredibly exciting, and I think it will be even faster together. #WMIF2021

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

4h

Congratulations! Benjamin Kleinstiver PhD, Massachusetts General Hospital, receives an Innovation Discovery Grant for “Towards a Permanent Genetic Cure for Spinal Muscular Atrophy” at #WMIF2021

@MassGeneralNews

@MGH_RI

@CGM_MGH

2

You Retweeted

Pearl Freier

@PearlF

·

10h

Listening to mRNA vaccines #wmif2021 panel w/ speakers incl SV Health managing partner & ex UK Vaccine Taskforce

@katebingham2

, Moderna CSO Platform Rsrch Melissa Moore,

@TranslateBio

CEO Ron Renaud

@biotech1969

, Brigham/BWH Dir Clinical Research Infectious Disease Lindsey Baden

2

2

You Retweeted

Ned Pagliarulo

@NedPagliarulo

·

May 19

FDA’s Peter Marks, at #WMIF2021, notes # of INDs for gene therapies was flat in 2020 vs. 2019. But the fact IND submissions didn’t decline, he said, is a sign of how strong the gene therapy field is, given pandemic’s disruption.

1

9

21



You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

5h

Coming up this afternoon: the 2021 Innovation Discovery Grants in #geneandcelltherapy. Who will secure additional funding for research to advance #GCT? Join us to watch live. #WMIF2021 https://worldmedicalinnovation.org/register/

2

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

1h

Thank you Jeannie Lee, MD PhD

@MGHPathology

, Bob Brown, PhD

@DicernaPharma

, Brett Monia, PhD

@ionispharma

, and Alfred Sandrock, MD PhD

@biogen

for sharing your perspectives on oligonucleotide-based therapies. #WMIF2021

1

2

You Retweeted

Pearl Freier

@PearlF

·

9h

Melissa Moore/Moderna- one advantage of mRNA is ability to do multivalent vaccines she said. She said they are already testing multivalent covid vaccines in clinical trials & testing flu vaccines. #wmif2021

1

3

You Retweeted

Pearl Freier

@PearlF

·

10h

Kate Bingham/SV Health & former head of UK Vaccine Taskforce: they haven’t seen escape variants in UK yet she said. mRNA is quickest platform to address escape variants probably. Needle delivery w/ supply cold chain has been the challenge. Deploying 3 vaccines in UK #WMIF2021

1

1

1

Show this thread

You Retweeted

Tracy Doyle

@doylet

·

6h

Marc Casper

@thermofisher

says gene and cell therapy represents a “phenomenal opportunity to improve patients’ lives” #WMIF2021 #GCT

1

2

You Retweeted

TranslateBio

@TranslateBio

·

7h

Today, our CEO Ron Renaud

@biotech1969

participated in

@MGBInnovation

‘s 2021 World Medical Innovation Forum to discuss the impact of #messengerRNA #vaccines on the industry #WMIF2021 #mRNA

2

10

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

6h

Lisa Deschamps, SVP & Chief Business Officer,

@NovartisGene

, notes that the science behind gene cell therapies is converging with technological development. How therapies are brought to market is still the question, as there is no roadmap when reimagining medicine #WMIF2021

3

4

You Retweeted

Pearl Freier

@PearlF

·

10h

Melissa Moore/Moderna: clear advantage of mRNA vaccine is how quickly we can manufacture the vaccines. Downsides- need 2store at low temperatures & limited shelflife 4storage in refrigerator. I know that both companies [Moderna, Pfizer/BioNTech] r working 2change this #wmif2021

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

6h

We’re committed to addressing the unmet needs of people living with rare genetic diseases. Our SVP, External Innovation and Strategic Alliances, Leah Bloom, discusses the promise #genetherapy holds for communities impacted by rare diseases during #WMIF2021.

2

4

You Retweeted

Tracy Doyle

@doylet

·

6h

Diagnostics and data tools key part of precision medicine complementing gene and cell therapy says

@KieranMurphyCEO

@GEHealthcare

at

@MGBInnovation

#WMIF2021

Meg Tirrell and 2 others

2

2

You Retweeted

Tracy Doyle

@doylet

·

7h

Debating the value of natural history studies in rare/ultra rare disease — panel led by Susan Slaugenhaupt, PhD, scientific director,

@MGH_RI

at #WMIF2021. Challenges include costs, feasibility, timing, comparative data.

1

2

You Retweeted

Tracy Doyle

@doylet

·

8h

Rett’s Syndrome, which primarily affects young girls, has historically been studied in male mice! Jeannie Lee, MD, PhD,

@MassGeneralNews

, and team are exploring how to treat the disease w X chromosome reactivation… and using a female mouse model. Hear more on #GCT at #WMIF2021

2

5

You Retweeted

Tracy Doyle

@doylet

·

10h

Speed of vaccination is critical to prevent escape variants says Kate Bingham, SV Health Investors, UK, at #WMIF2021, exploring what’s next for the technology w panel led by Lindsey Baden MD,

@BrighamWomens

2

2

May 19, 2021

TWEETS AND RE-TWEETS for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021

PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 19, 2021

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 19, 2021

Tweets Originator for Part 1: Aviva Lev-Ari, PhD, RN

Example for a TWEET

Aviva Lev-Ari

@AVIVA1950

·

May 21

@MGBInnovation

#WMIF Best Global event on Gene Cell Therapy covered in real time

@AVIVA1950

@pharma_BI

Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

2

2

Example for a RE-TWEET

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 21

Thanks

@AVIVA1950

for sharing this screen capture of the impressive lineup of #GCT “Disruptive Dozen” panelists at #WMIF2021

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · May 21

@MGBInnovation #WMIF Best Global event on Gene Cell Therapy covered in real time @AVIVA1950 @pharma_BI Disruptive Dozen technologies four are based on Gene Editing, AAV and non viral vector for drug delivery are included

 PART 1: ALL THE TWEETS PRODUCED by @AVIVA1950 on May 19, 2021



Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Marcela Maus, MD, PhD Director, Cancer Center, MGH, HMS  Fit-to-purpose CAR-T cells: 3 lead programs Tr-fill CAR-T induce response myeloma and multiple myeloma GBM 27 patents on CAR-T +400 patients treaded 40 Clinical Trials 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Thomas VanCott, PhD Global Head of Product Dev, Gene & Cell Therapy, Catalent 2/3 autologous 1/3 allogeneic  CAR-T high doses scale up is not done today logistics issues centralized vs decentralized allogeneic are health donors

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Ropa Pike, Director,  Enterprise Science & Partnerships, Thermo FIsher Scientific  Centralized biopharma industry is moving  to decentralized models site specific license 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

17h

#WMIF2021

@MGBInnovation

Rahul Singhvi, ScD CEO and Co-Founder, National Resilience, Inc. Investment company in platforms to be shared by start ups in CGT. Production cost of allogeneic: cost of quality 30% reagents 30% cell 30% Test is very expensive 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Oladapo Yeku, MD, PhD Clinical Assistant in Medicine, MGH Outstanding moderator and most gifted panel on solid tumor success window of opportunities studies 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Knut Niss, PhD CTO, Mustang Bio tumor hot start in 12 month clinical trial solid tumors Combination therapy will be an experimental treatment long journey checkpoint inhibitors to be used in combination maintenance 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Barbra Sasu, PhD CSO, Allogene T cell response at prostate cancer  tumor specific  cytokine tumor specific signals move from solid to metastatic cell type for easier infiltration

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Jennifer Brogdon Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR 2017 CAR-T first approval M&A and research collaborations TCR tumor specific antigens avoid tissue toxicity 

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Jay Short, PhD Chairman, CEO, Cofounder, BioAlta, Inc. Tumor type is not enough for R&D therapeutics other organs are involved in periphery difficult to penetrate solid tumors biologics activated in the tumor only, positive changes

@pharma_BI

@AVIVA1950

1

1

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Christi Shaw CEO, Kite CAR-T is priority 120 companies in the space Manufacturing consistency  Patients respond with better quality of life

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

18h

#WMIF2021

@MGBInnovation

Stefan Hendriks Global Head, Cell & Gene, Novartis Confirmation the effectiveness of CAR-T therapies, 1 year response to 5 years 26 months Patient not responding a lot to learn Patient after 8 months of chemo can be helped by CAR-T

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

19h

#WMIF2021

@MGBInnovation

Jeffrey Infante, MD , Oncology, Janssen R&D Direct effect with intra-tumor single injection with right payload Platform approach  Prime with 1 and Boost with 2 – not yet experimented with  Do not have the data at trial

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

19h

#WMIF2021

@MGBInnovation

Nino Chiocca, MD, PhD Neurosurgeon-in-Chief BWH, HMS Oncolytic therapy DID NOT WORK Pancreatic Cancer and Glioblastoma Intra-tumoral heterogeniety hinders success Oncolytic VIRUSES – “coldness” GADD-34 20,000 GBM 40,000 pancreatic

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

19h

#WMIF2021

@MGBInnovation

Loic Vincent, PhD Head of Oncology Drug Discovery Unit, Takeda Classification of Patients by prospective response type id UNKNOWN yet, population of patients require stratification

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Loic Vincent, PhD Head of Oncology Drug Discovery Unit, Takeda R&D in collaboration with Academic Vaccine platform to explore different payload IV administration may not bring sufficient concentration to the tumor is administer IV

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Nino Chiocca, MD, PhD Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH Harvey W. Cushing Professor of Neurosurgery, HMS Challenges of manufacturing at Amgen what are they?

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

David Reese, MD Executive Vice President, R&D , Amgen Inter lesion injection of agent vs systemic therapeutics cold tumors immune resistant render them immune susptible Oncolytic virus is a Mono therapy addressing the unknown 

@pharma_BI

@AVIVA1950

2

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

David Reese, MD Executive Vice President, Research and Development, Amgen Inter lesion injection of agent vs systemic therapeutics  cold tumors immune resistant render them immune suseptible Oncolytic virus is a Mono therapy

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Robert Coffin, PhD Chief R&D Officer, Replimune 2002 in UK promise in oncolytic therapy GNCSF Phase III melanoma 2015 M&A with Amgen oncolytic therapy remains non effecting on immune response data is key for commercialization 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

20h

#WMIF2021

@MGBInnovation

Ann Silk, MD Physician, Dana Farber-Brigham and Women’s Cancer Center, HMS Which person gets oncolytics virus if patient has immune supression due to other indications Safety of oncolytic virus greater than Systemic treatment

@pharma_BI

@AVIVA1950

2

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

@pharma_BI

@AVIVA1950

amazing Conference on the frontier od Science Cell & Gene Therapy

@MGB

top programs for ALS, Brain genetic vasculopathologies and Occular, MEE

@pharma_BI

@AVIVA1950

Quote Tweet

Pearl Freier

@PearlF

 · 21h

Marianne De Backer/Bayer on post M&A & company culture: They acquired AskBio & thought about how to preserve their freedom so they could continue to operate. Bayer decided to keep them independent & so they can operate at arm’s length. #wmif2021



Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Merit Cudkowicz, MD Chief of Neurology, MGH ALS – Man 1in 300, Women 1 in 400, next decade increase 7%  10% ALS is heredity 160 pharma in ALS space diagnosis is late 1/3 of people are not diagnosed active community for clinical trials @pharma_BI@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Adam Koppel, MD, PhD Managing Director, Bain Capital Life Sciences What acquirers are looking for?? What is the next generation vs what is real where is the industry going?

@pharma_BI

@AVIVA1950

2

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Debby Baron, Worldwide Business Development, Pfizer  Scalability and manufacturing regulatory conversations, clinical programs safety in parallel to planning getting drug to patients

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Marianne De Backer, PhD Head of Strategy, BD & Licensing, Bayer Absolute Leadership: Gene editing, gene therapy, via acquisition and alliances Operating model of the acquired company discussed acquired continue independence

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Sean Nolan Board Chairman, Encoded Therapeutics & Affinia Executive Chairman Jaguar Gene Therapy Istari Oncology As acquiree multiple M&A acquirer looks at integration and cultures companies  Traditional integration vs acquisition 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Debby Baron, Worldwide Business Development, Pfizer  CGT is an important area Pfizer is active looking for innovators, advancing forward programs of innovation with the experience Pfizer has internally 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

Marianne De Backer, PhD Head of Strategy, Business Development & Licensing, and Member of the Executive Committee, Bayer Absolute Leadership in Gene editing, gene therapy, via acquisition and strategic alliance 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

22h

2 people unfollowed me // automatically checked by

fllwrs – keep track of who follows and unfollows you on twitter

fllwrs is the easiest way to keep track of your twitter followers

fllwrs.com

Aviva Lev-Ari

@AVIVA1950

·

22h

#WMIF2021

@MGBInnovation

Manny Simons, PhD CEO, Akouos Biology across species nerve ending in the cochlea engineer out of the caspid, lowest dose possible, get desired effect by vector use, 2022 new milestones

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

22h

#WMIF2021

@MGBInnovation

Mathew Pletcher, PhD SVP, Head of Gene Therapy Research and Technical Operations, Astellas Continue to explore large animal guinea pig not the mice, not primates (ethical issues) for understanding immunogenicity and immune response 

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

22h

#WMIF2021

@MGBInnovation

Mathew Pletcher, PhD SVP, Head of Gene Therapy Research and Technical Operations, Astellas Work with diseases poorly understood, collaborations needs example of existing: DMD is a great example explain dystrophin share placedo data 

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Rick Modi CEO, Affinia Therapeutics Speed R&D Speed better gene construct get to clinic with better design vs ASAP Data sharing clinical experience patients selection, vector selection, mitigation, patient type specific

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Dave Lennon, PhD President, Novartis Gene Therapies big pharma therapeutics not one drug across Tx areas: cell, gene iodine therapy collective learning infrastructure development Acquisitions growth # applications for scaling 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Rick Modi CEO, Affinia Therapeutics Copy, paste EDIT from product A to B novel vectors variant of vector coder optimization choice of indication is critical exploration on larger populations Speed to R&D to better gene construct get

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

23h

#WMIF2021

@MGBInnovation

Louise Rodino-Klapac, PhD EVP, Chief Scientific Officer, Sarepta Therapeutics AV based platform 15 years in development 1 disease indication vs more than one indication stereotype, analytics as hurdle 1st was 10 years 2nd was 3 years

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Katherine High, MD President, Therapeutics, AskBio Three drugs approved in Europe in the CGT Regulatory Infrastructure CGT drug approval – as new class of therapeutics Participants investigators, regulators, patients i.e., MDM 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Peter Marks, MD, PhD Director, Center for Biologics Evaluation and Research, FDA Immune modulators Immunotherapy Genome editing can make use of viral vectors future technologies nanoparticles and liposome encapsulation 50% more staff

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Peter Marks, MD, PhD Director, Center for Biologics Evaluation and Research, FDA Recover Work load for the pandemic Gene Therapies IND application remained flat Rare diseases urgency remains Guidance T-Cell therapy vs Regulation

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Peter Marks, MD, PhD Director, Center for Biologics Evaluation and Research, FDA June 2020 belief that vaccine challenge manufacture scaling up FDA did not predicted the efficacy of mRNA vaccine vs other approaches expected to work

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Jim Holland CEO, http://Backcountry.com Parkinson patient Constraints by regulatory on participation in clinical trial wish to take Information dissemination is critical 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Patricia Musolino, MD, PhD Co-Director Pediatric Stroke and Cerebrovascular Program What is the Power of One – the impact that a patient can have on their own destiny connecting with other participants in same trial can be beneficial

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Barbara Lavery Chief Program Officer, ACGT Foundation Patient has the knowledge of the symptoms and recording all input needed for diagnosis by multiple clinicians Early application for CGT

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Sarah Beth Thomas, RN Professional Development Manager, BWH Outcome is unknown, hope for good, support with resources all advocacy groups, 

@pharma_BI

@AVIVA1950



Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Jack Hogan Patient, MEE Constraints by regulatory on participation in #clinicaltrials advance stage is approved participation Patients to determine the level of #risk they wish to take 

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Barbara Lavery Chief Program Officer, ACGT Foundation Advocacy agency beginning of work Global Genes educational content and out reach to access the information

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Dave Lennon, PhD President, Novartis Gene Therapies Modality one time intervention, long duration of impart, reimbursement, ecosystem FDA works by indications and risks involved, Standards manufacturing payments over time payers

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Dave Lennon, PhD President, Novartis Gene Therapies Promise of CGT realized, what part? #FDA role and interaction in CGT #Manufacturing aspects which is critical

@pharma_BI

@AVIVA1950

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Julian Harris, MD Partner, Deerfield Hope that CGT emerging, how therapies work, #neuro, #muscular, #ocular, #genetic diseases of #liver and of #heart revolution for the industry 900 #IND application 25 approvals #Economic driver 

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Luk Vandenberghe, PhD Grousbeck Family Chair, Gene Therapy, MEE Associate Professor, Ophthalmology, HMS #Pharmacology #Gene-Drug, Interface academic centers and industry many CGT drugs emerged in Academic center

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Ravi Thadhani, MD CAO, Mass General Brigham Professor, Medicine and Faculty Dean, HMS Role of #academia special to spear head the #Polygenic #therapy – multiple #genes involved, #plug-play #delivery

@pharma_BI

@AVIVA1950

1

Aviva Lev-Ari

@AVIVA1950

·

May 19

#WMIF2021

@MGBInnovation

Nino Chiocca, MD, PhD Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH #Oncolytic #Viruses triple threats #Toxic, #braintumors #immunological requires #combination #therapies with #anticancer

@pharma_BI

@AVIVA1950

Part 2: ALL THE RE-TWEETS by @AVIVA1950 on

May 19, 2021

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

17h

Will point of care production become a reality? “Short answer is yes” says Rupa Pike PhD, Director, Enterprise Science & Innovation Partnerships,

@thermofisher

. #WMIF2021 #GCTManufacturing

2

2

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 18

The field of #genetherapy is growing. New therapies will come to market for rare and chronic diseases, and new therapies will drive scientific innovation and economic growth. #WMIF2021 (2/6)

1

1

1

Show this thread

Aviva Lev-Ari

@AVIVA1950

·

15h

Very creative two targets

@ScaddenLab

@pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 16h

A behind the scenes look at David Scadden, MD @ScaddenLab presenting his FIRST LOOK: Regenerating T Cell Immunity #WMIF2021 #GCT #Tcells

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

16h

In our First Look sessions clinicians/researchers from Harvard-affiliated hospitals highlight the potential of their research & new technologies. Next we’ll hear from Khalid Shah PhD, Vice Chair of Research

@BWHNeurosurgery

#WMIF2021 https://bwhclinicalandresearchnews.org/2021/05/11/look-whos-talking-world-medical-innovation-forum-first-look-speakers/…

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

19h

“Entrepreneurial Growth | Oncolytic Virus” panel, moderated by Reid Huber PhD, Partner

@ThirdRockV

, discusses how small companies can address the challenges of developing #oncolyticvirus therapies. #WMIF2021

3

3

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 19

The World Medical Innovation Forum is here! During his fireside chat, our President Dave Lennon shares the immense promise ahead for #genetherapy.

@MGBInnovation

#WMIF2021

1

3

6

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 18

Tomorrow is Day 1 of #WMIF2021! Hear from the world-renowned CEOs, investors, clinicians and scientists bringing game-changing discoveries and insights to #GCT. Register to attend today: https://worldmedicalinnovation.org/register/

2

1

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 18

We’re at

@MGBInnovation

‘s World Medical Innovation Forum this week, discussing the future of #genetherapy. Here are our five predictions for where the industry is headed. #WMIF2021 (1/6)

1

1

4

Show this thread

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

23h

Some incredible #visualnotes from this morning’s co-chair’s panel “The Grand Challenge of Widespread GCT Patient Benefits” #WMIF2021 #GCT #geneandcelltherapy

1

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 17

The World Medical Innovation Forum #WMIF2021 is just two days away! Join us to hear the latest in #geneandcelltherapy #healthcare innovation. https://worldmedicalinnovation.org/register/

You Retweeted

BrighamResearch

@BrighamResearch

·

May 16

“We anticipate that our engineered tumor cell platform will have major contributions in finding a cure for #glioblastoma patients,” says

@khalidshahs

 of

@BWHNeurosurgery

. Catch a preview of his #WMIF2021 First Look talk here: https://fal.cn/3fpUL

8

16

You Retweeted

Mass Eye and Ear

@MassEyeAndEar

·

22h

Dr. Eric Pierce

@MassEyeAndEar

@HMSeye

explains at #WMIF2021 why the first FDA-approved gene therapy for inherited disease was for an inherited retinal degeneration, and what lessons have been learned from the success of that treatment.

Mass General Brigham Innovation

6

11

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

22h

Ravi Thadhani, CAO @MassGeneralBrigham and Juergen Eckhardt, Head of

@LeapsbyBayer

, will be announcing the 2021 Innovation Discovery Grants at #WMIF2021 tomorrow, 5/20 @ 2:00 pm Eastern. https://worldmedicalinnovation.org

Quote Tweet

Leaps by Bayer

@LeapsByBayer

 · 22h

Together with @BayerPharma, we are pleased to be part of #WMIF2021, organized by @MassGenBrigham. This year’s event focuses on the transformative potential of #cellandgene therapy (#GCT).

Show this thread

 

1

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

20h

Welcome back! Our next #WMIF2021 panel, Oncolytic Viruses in #Cancer | Curing #Melanoma and Beyond, features panelists from

@BrighamWomens

@Replimune

@EikonTX

@Amgen

and

@DanaFarber

2

6

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

22h

“We are more committed to our mission than ever before – laser-focused on realizing the transformative potential of #genetherapy for patients.” – Dave Lennon, President, during #WMIF2021

Outstanding researcher and speaker

@pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 21h

Patricia Musolino, MD PhD, Co-Director Pediatric Stroke and Cerebrovascular Program at MGH, discusses her work developing #genetherapy treatments for cerebral genetic vasculopathies #GCT #geneandcelltherapy #WMIF2021

1

You Retweeted

Mass Eye and Ear

@MassEyeAndEar

·

23h

Happening now at #WMIF2021.

@MassEyeAndEar

chief and

@HMSeye

chair Dr. Joan Miller moderates a panel on AAV gene therapy featuring director of Inherited Retinal Disorders Service and Ocular Genomics Institute, Dr. Eric Pierce.

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 23h

Our “AAV Success Studies | Retinal Dystrophy | Spinal Muscular Atrophy” panelists have taken the stage. #WMIF2021 @MassEyeAndEar @REGENXBIO @spark_tx @NovartisGene

1

3

You Retweeted

CRISPR Therapeutics

@CRISPRTX

·

19h

Attending

@MGBInnovation

World Medical Innovation Forum? Tune in to hear our CEO

@CRISPRSam

speak tomorrow at 3:25pm ET on innovations in cell and gene therapy, followed by a Q&A. Learn more: https://bit.ly/3eWb66R #WMIF2021

4

22

You Retweeted

Biogen

@biogen

·

15h

We are proud sponsors of the Virtual World Medical Innovation Forum (#WMIF2021). This year’s program will focus on the impact of gene and cell therapy as a way to potentially advance quality patient care, reduce cost and improve outcomes. Learn more:

World Medical Innovation Forum

worldmedicalinnovation.org

You Retweeted

Pearl Freier

@PearlF

·

16h

Jonathan Kraft introducing #wmif2021 session with Pfizer CSO & president of R&D Mikael Dolsten and MGH oncologist & chair of MGH Cancer Center Daniel Haber.

1

1

Aviva Lev-Ari

@AVIVA1950

·

15h

MEE is the leader in cell therapy for retina genetic disease

Quote Tweet

Tracy Doyle

@doylet

 · May 19

Great discussion to open #WMIF2021 on the patient impact of #GCT @MGBInnovation World Medical Innovation Forum twitter.com/AVIVA1950/stat…

You Retweeted

Pearl Freier

@PearlF

·

May 19

Tuning into

@MGBInnovation

#WMIF2021 cell & gene therapy meeting.

@NovartisGene

president Dave Lennon & Deerfield partner Julian Harris having a “fireside chat.” Dave/Novartis: sees gene therapy as driver for economy generating need for highly skilled workers Incl manufacturing

2

5

You Retweeted

Pearl Freier

@PearlF

·

17h

Kite Pharma CEO (Gilead subsidiary) Christi Shaw said there are 120 biopharma companies working on CAR-T cell therapy & they are continuing to look for new partnerships. She also mentioned logistical challenges currently getting to Israel & helping patients there. #WMIF2021

2

3

You Retweeted

Pearl Freier

@PearlF

·

15h

Dolsten/Pfizer discussing their partnership with Ionis.https://ir.ionispharma.com/news-releases/news-release-details/ionis-and-akcea-announce-pfizer-has-initiated-phase-2b-clinical… #wmif2021

Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA…

The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.’s business for stockholders, potential investors, and financial analysts.

ir.ionispharma.com

1

1

You Retweeted

Pearl Freier

@PearlF

·

23h

FDA’s Dir of Center for Biologics Evaluation & Research Peter Marks interviewed by Vicki Sato- chairwoman of Vir Biotechnology, ex Vertex president & ex Biogen VP Research. Around June ’20, started 2c progress in covid vaccines w/ enough candidates moving forward #WMIF2021 1/n

1

2

You Retweeted

Tracy Doyle

@doylet

·

23h

FDA staffing up on gene therapies personnel by 50% says Peter Marks, MD, PhD, Center for Biologics Evaluation and Research

@US_FDA

at #WMIF2021

1

1

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

18h

“Once you work on cell and gene therapy, its really hard to go back and work on anything else” says moderator Marcela Maus, MD PhD in our “CAR-T | Lessons Learned | What’s Next” panel #WMIF2021 #GCT #geneandcelltherapy

2

1

You Retweeted

Pearl Freier

@PearlF

·

20h

Ex Merck president R&D Roger Perlmutter is now Eikon Therapeutics CEO & is on #WMIF2021 oncolytic virus in cancer panel w/Amgen EVP R&D David Reese, ex BioVex CTO (T-VEC inventor

@robertcoffin3

now

@Replimune

founder/president, Dana-Farber physician Ann Silk, BWH’s Nino Chiocca

You Retweeted

Novartis Gene Therapies

@NovartisGene

·

May 18

During this week’s World Medical Innovation Forum with

@MassGenBrigham

, join our leaders for panels and presentations discussing what’s next for #genetherapy and the key trends shaping the industry as it evolves. #WMIF2021 https://bit.ly/3eYYls4

59 views

0:24 / 0:36

1

4

You Retweeted

Pearl Freier

@PearlF

·

16h

Dolsten/Pfizer discussed covid vaccines and real world evidence study in Israel. Was sole provider of vaccines in Israel. 95%-98% efficacy replicated in real world. Well above 90% efficacy in asymptomatic disease. #wmif2021

2

4

You Retweeted

Tracy Doyle

@doylet

·

18h

Is CART-T therapy still an industry priority? Panelists say yes! Join us to hear more at the

@MGBInnovation

#WMIF2021

2

2

You Retweeted

Pearl Freier

@PearlF

·

18h

CAR-T #WMIF2021 panel w/ MGH’s

@MarcelaMaus

,

@Atarabio

EVP R&D

@jdupontmd

, BMS SVP Hematology/Oncology & Cell Therapy

@KristenHege

,

@KitePharma

CEO Christi Shaw, Novartis Global Head Cell & Gene

@Stefanhendriks5

1

3

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

16h

ICYMI: An illustration depicting the “AAV Delivery” panel discussion about advances in the area of #AAVGeneTherapy delivery. Thank you to the panelists from

@MGHNeurology

,

@CureFA_org

,

@AstellasUS

and

@AkouosInc

. #geneandcelltherapy #GCT #WMIF2021



Aviva Lev-Ari

@AVIVA1950

·

16h

Like that presentation a lot

@pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 22h

Casey Maguire PhD, Associate Professor of Neurology, at the podium to present his work developing improved #genetherapy vectors. #WMIF2021 “First Look: Enhanced Gene Delivery and Immunoevasion of AAV Vectors without Capsid Modification”

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

22h

Casey Maguire PhD, Associate Professor of Neurology, at the podium to present his work developing improved #genetherapy vectors. #WMIF2021 “First Look: Enhanced Gene Delivery and Immunoevasion of AAV Vectors without Capsid Modification”

3

3

Aviva Lev-Ari

@AVIVA1950

·

16h

Best interview of a CSO in the history of Big Pharma

@Pharma_BI

@AVIVA1950

Quote Tweet

Mass General Brigham Innovation

@MGBInnovation

 · 16h

Mikael Dolsten, MD PhD, CSO & President, Worldwide Research, Development and Medical @pfizer takes the stage for a Fireside Chat, moderated by @MGHCancerCenter Daniel Haber, MD, PhD. “Pfizer’s Future in Cell and Gene Therapy” #WMIF2021

You Retweeted

Pearl Freier

@PearlF

·

May 19

Dave Lennon/Novartis: manufacturing has been a roadblock for many cell & gene therapy companies. Expects to see more investments earlier. Engineering advances will unlock scale & address bigger & bigger patient populations. Oppty to ID patients early #WMIF2021

3

5

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

19h

Nino Chiocca, MD PhD,

@BWHNeurosurgery

presents FIRST LOOK: Oncolytic Viruses: Turning Pathogens into Anticancer Agents #WMIF2021

You Retweeted

Pearl Freier

@PearlF

·

22h

M&A cell & gene therapy #WMIF2021 panel incl Bain Capital’s Adam Koppel, Bayer’s Head Strategy Business Development & Licensing

@MDDBacker

, Pfizer’s SVP Worldiwde BD Debbie Baron, Eli Lilly VP BD Ken Custer, ex AveXis CEO Sean Nolan now Affinia & Encoded Therapeutics Board Chair

2

6

You Retweeted

Pearl Freier

@PearlF

·

21h

Marianne De Backer/Bayer on post M&A & company culture: They acquired AskBio & thought about how to preserve their freedom so they could continue to operate. Bayer decided to keep them independent & so they can operate at arm’s length. #wmif2021

3

4

You Retweeted

Resilience

@IncResilience

·

17h

Happening now: our CEO, Rahul Singhvi, speaking at the virtual 2021 World Medical Innovation Forum: http://worldmedicalinnovation.org #WMIF2021 https://pic.twitter.com/Nyc2lXbvUR

3

6

You Retweeted

Pearl Freier

@PearlF

·

21h

Ken Custer/Eli Lilly-said they’re relatively new in cell & gene therapy. They invested in 1 of Sean Nolan’s (ex AveXis CEO) new companies,Jaguar Gene Therapy. Lilly’s legacy in neuroscience is noted & bought Prevail last yr. Clinical trial w/ Parkinson’s w/GBA1 mutation #wmif2021

2

2

You Retweeted

Mass General Brigham Innovation

@MGBInnovation

·

May 19

Jack Hogan, a patient

@MassEyeAndEar

, was the first in the U.S. to be approved for FDA gene therapy surgery. In 2018 he underwent therapy to treat retinitis pigmentosa by having a synthetic gene inserted into his retina. With improved eyesight he can now play sports #WMIF2021

3

11

You Retweeted

Tracy Doyle

@doylet

·

21h

The acquisition market in #GCT: looking for breakthroughs for patients, technologies for intractable diseases, manufacturing expertise, pioneering companies with deep experience — all for “the modality of the future”. M&A panel at #WMIF2021

2

2

You Retweeted

Pearl Freier

@PearlF

·

18h

Christi Shaw/Kite Pharma: Only 4 out of 10 patients eligible for CAR-T are being referred for CAR-T cell therapy by oncologists. The other 6 out of 10, referred to palliative care only. Consistency of manufacturing is also very important. #wmif2021 1/n

1

10

20

Show this thread

You Retweeted

Mass Eye and Ear

@MassEyeAndEar

·

22h

AAV gene therapy expert

@VandenbergheLuk

@HMSeye

@MassEyeAndEar

presents on the future potential of this revolutionary technology at #WMIF2021

Aviva Lev-Ari

@AVIVA1950

·

21h

#WMIF2021

@MGBInnovation

@pharma_BI

@AVIVA1950

amazing Conference on the frontier od Science Cell & Gene Therapy

@MGB

top programs for ALS, Brain genetic vasculopathologies and Occular, MEE

@pharma_BI

@AVIVA1950

Quote Tweet

Pearl Freier

@PearlF

 · 21h

Marianne De Backer/Bayer on post M&A & company culture: They acquired AskBio & thought about how to preserve their freedom so they could continue to operate. Bayer decided to keep them independent & so they can operate at arm’s length. #wmif2021

The Nobel Prize in Chemistry 2021

Reporter: Aviva Lev-Ari, PhD, RN

6 October 2021

The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2021

to

Benjamin List
Max-Planck-Institut für Kohlenforschung, Mülheim an der Ruhr, Germany

David W.C. MacMillan
Princeton University, USA

“for the development of asymmetric organocatalysis”

Meet UC’s 2021 Nobelists

Three UC-affiliated scientists have won Nobel Prizes this year: UCSF professor David Julius, UCLA alum Ardem Patapoutian and UC Irvine alum David W.C. MacMillan.

SOURCE

UC’s new Nobelists
UC San Francisco, UCLA and UC Irvine
Three UC-affiliated scientists were awarded Nobel Prizes this week. UC San Francisco professor David Julius shared the Nobel Prize in physiology or medicine with UCLA alum Ardem Patapoutian. UC Irvine alum David W.C. MacMillan won in chemistry. 

From: University of California <webeditor@ucop.edu>
Reply-To: University of California <webeditor@ucop.edu>
Date: Friday, October 8, 2021 at 1:02 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: 3 UC Nobel Prize winners!

IMAGE SOURCE:
Chemistry Nobel Prize Honors Technique for Building Molecules. Benjamin List and David MacMillan received the 2021 Nobel Prize in Chemistry for their development of asymmetrical organocatalysis. https://www.quantamagazine.org/chemistry-nobel-prize-honors-technique-for-building-molecules-20211006/

An ingenious tool for building molecules

Building molecules is a difficult art. Benjamin List and David MacMillan are awarded the Nobel Prize in Chemistry 2021 for their development of a precise new tool for molecular construction: organocatalysis. This has had a great impact on pharmaceutical research, and has made chemistry greener.

Many research areas and industries are dependent on chemists’ ability to construct molecules that can form elastic and durable materials, store energy in batteries or inhibit the progression of diseases. This work requires catalysts, which are substances that control and accelerate chemical reactions, without becoming part of the final product. For example, catalysts in cars transform toxic substances in exhaust fumes to harmless molecules. Our bodies also contain thousands of catalysts in the form of enzymes, which chisel out the molecules necessary for life.

Catalysts are thus fundamental tools for chemists, but researchers long believed that there were, in principle, just two types of catalysts available: metals and enzymes. Benjamin List and David MacMillan are awarded the Nobel Prize in Chemistry 2021 because in 2000 they, independent of each other, developed a third type of catalysis. It is called asymmetric organocatalysis and builds upon small organic molecules.

“This concept for catalysis is as simple as it is ingenious, and the fact is that many people have wondered why we didn’t think of it earlier,” says Johan Åqvist, who is chair of the Nobel Committee for Chemistry.

Organic catalysts have a stable framework of carbon atoms, to which more active chemical groups can attach. These often contain common elements such as oxygen, nitrogen, sulphur or phosphorus. This means that these catalysts are both environmentally friendly and cheap to produce.

The rapid expansion in the use of organic catalysts is primarily due to their ability to drive asymmetric catalysis. When molecules are being built, situations often occur where two different molecules can form, which – just like our hands – are each other’s mirror image. Chemists will often only want one of these, particularly when producing pharmaceuticals.

Organocatalysis has developed at an astounding speed since 2000. Benjamin List and David MacMillan remain leaders in the field, and have shown that organic catalysts can be used to drive multitudes of chemical reactions. Using these reactions, researchers can now more efficiently construct anything from new pharmaceuticals to molecules that can capture light in solar cells. In this way, organocatalysts are bringing the greatest benefit to humankind.

Benjamin List, born 1968 in Frankfurt, Germany. Ph.D. 1997 from Goethe University Frankfurt, Germany. Director of the Max-Planck-Institut für Kohlenforschung, Mülheim an der Ruhr, Germany.

David W.C. MacMillan, born 1968 in Bellshill, UK. Ph.D. 1996 from University of California, Irvine, USA. Professor at Princeton University, USA.

Prize amount: 10 million Swedish kronor, to be shared equally between the Laureates.
Further information: http://www.kva.se and http://www.nobelprize.org

SOURCE

https://www.nobelprize.org/prizes/chemistry/2021/press-release/

Scientific Background: Enamine and iminium ion-mediated organocatalysis (pdf)

Chemistry Nobel Prize Honors Technique for Building Molecules

by Jordana Cepelewicz

https://www.quantamagazine.org/chemistry-nobel-prize-honors-technique-for-building-molecules-20211006/

The Nobel Prize in Physiology or Medicine 2021 was awarded jointly to David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch.”

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 10/14/2021

49th (2019) – Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research

for their remarkable contributions to our understanding of the sensations of temperature, pain and touch

David Julius – 49th (2019) – Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research

for their remarkable contributions to our understanding of the sensations of temperature, pain and touch


(2021 Nobel Prize)
Morris Herzstein Chair in Molecular Biology and Medicine
Professor and Chair, Department of Physiology
School of Medicine
The University of California, San Francisco
San Francisco, CA USA

Ardem Patapoutian – 49th (2019) – Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research for their remarkable contributions to our understanding of the sensations of temperature, pain and touch


(2021 Nobel Prize)

Investigator, Howard Hughes Medical Institute
Professor, Department of Neuroscience
The Scripps Research Institute
La Jolla, CA USA

Press release: The Nobel Prize in Physiology or Medicine 2021. NobelPrize.org. Nobel Prize Outreach AB 2021. Mon. 4 Oct 2021. <https://www.nobelprize.org/prizes/medicine/2021/press-release/>

David Julius was born in 1955 in New York, USA. He received a Ph.D. in 1984 from University of California, Berkeley and was a postdoctoral fellow at Columbia University, in New York. David Julius was recruited to the University of California, San Francisco in 1989 where he is now Professor.

Ardem Patapoutian was born in 1967 in Beirut, Lebanon. In his youth, he moved from a war-torn Beirut to Los Angeles, USA and received a Ph.D. in 1996 from California Institute of Technology, Pasadena, USA. He was a postdoctoral fellow at the University of California, San Francisco. Since 2000, he is a scientist at Scripps Research, La Jolla, California where he is now Professor. He is a Howard Hughes Medical Institute Investigator since 2014.

Meet UC’s 2021 Nobelists

Three UC-affiliated scientists have won Nobel Prizes this year: UCSF professor David Julius, UCLA alum Ardem Patapoutian and UC Irvine alum David W.C. MacMillan.

SOURCE

UC’s new Nobelists
UC San Francisco, UCLA and UC Irvine
Three UC-affiliated scientists were awarded Nobel Prizes this week. UC San Francisco professor David Julius shared the Nobel Prize in physiology or medicine with UCLA alum Ardem Patapoutian. UC Irvine alum David W.C. MacMillan won in chemistry. 

From: University of California <webeditor@ucop.edu>
Reply-To: University of California <webeditor@ucop.edu>
Date: Friday, October 8, 2021 at 1:02 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: 3 UC Nobel Prize winners!

Key publications

Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997:389:816-824.

Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998:21:531-543.

Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000:288:306-313

McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002:416:52-58

Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, Patapoutian A. A TRP channel that senses cold stimuli and menthol. Cell 2002:108:705-715

Coste B, Mathur J, Schmidt M, Earley TJ, Ranade S, Petrus MJ, Dubin AE, Patapoutian A. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science 2010:330: 55-60

Ranade SS, Woo SH, Dubin AE, Moshourab RA, Wetzel C, Petrus M, Mathur J, Bégay V, Coste B, Mainquist J, Wilson AJ, Francisco AG, Reddy K, Qiu Z, Wood JN, Lewin GR, Patapoutian A. Piezo2 is the major transducer of mechanical forces for touch sensation in mice. Nature 2014:516:121-125

Discoveries by this year's Nobel Prize laureates
Figure 4 The seminal discoveries by this year’s Nobel Prize laureates have explained how heat, cold and touch can initiate signals in our nervous system. The identified ion channels are important for many physiological processes and disease conditions.

IMAGE SOURCE: https://www.nobelprize.org/prizes/medicine/2021/press-release/


The science heats up!

In the latter part of the 1990’s, David Julius at the University of California, San Francisco, USA, saw the possibility for major advances by analyzing how the chemical compound capsaicin causes the burning sensation we feel when we come into contact with chili peppers. Capsaicin was already known to activate nerve cells causing pain sensations, but how this chemical actually exerted this function was an unsolved riddle. Julius and his co-workers created a library of millions of DNA fragments corresponding to genes that are expressed in the sensory neurons which can react to pain, heat, and touch. Julius and colleagues hypothesized that the library would include a DNA fragment encoding the protein capable of reacting to capsaicin. They expressed individual genes from this collection in cultured cells that normally do not react to capsaicin. After a laborious search, a single gene was identified that was able to make cells capsaicin sensitive (Figure 2). The gene for capsaicin sensing had been found! Further experiments revealed that the identified gene encoded a novel ion channel protein and this newly discovered capsaicin receptor was later named TRPV1. When Julius investigated the protein’s ability to respond to heat, he realized that he had discovered a heat-sensing receptor that is activated at temperatures perceived as painful (Figure 2).

David Julius' work
Figure 2 David Julius used capsaicin from chili peppers to identify TRPV1, an ion channel activated by painful heat. Additional related ion channels were identified and we now understand how different temperatures can induce electrical signals in the nervous system.

The discovery of TRPV1 was a major breakthrough leading the way to the unravelling of additional temperature-sensing receptors. Independently of one another, both David Julius and Ardem Patapoutian used the chemical substance menthol to identify TRPM8, a receptor that was shown to be activated by cold. Additional ion channels related to TRPV1 and TRPM8 were identified and found to be activated by a range of different temperatures. Many laboratories pursued research programs to investigate the roles of these channels in thermal sensation by using genetically manipulated mice that lacked these newly discovered genes. David Julius’ discovery of TRPV1 was the breakthrough that allowed us to understand how differences in temperature can induce electrical signals in the nervous system.

SOURCE

https://www.nobelprize.org/prizes/medicine/2021/press-release/

Tweets and Re-Tweets of Tweets by @pharma_BI@AVIVA1950   at EmTech MIT 2021,  #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021

REAL TIME EVENT COVERAGE as PRESS by invitation from EmTech MIT 2021 at #EmTechMIT:

Aviva Lev-Ari, PhD, RN

Tweet Collection Curator:

Aviva Lev-Ari, PhD, RN

TWEET HIGHLIGHTS

Top Tweet earned 24K impressions

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

 2  10

View all Tweet activityView Tweet activity

Top Follower followed by 18.9K people

Julien Rio, CCXP 🚀

@Marketing_JR FOLLOWS YOU

#CCXP#marketing expert, #keynotespeaker#author#CX evangelist & #entrepreneur. AVP Marketing @ @RingCentral | French & English

View profile

Top mention earned 126 engagements

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

 2  10

View all Tweet activityView Tweet activity

SEP 2021 SUMMARY

Tweets

96

Tweet impressions

58.5K

Profile visits

572

Mentions

94

New followers

11

Selective Retweets of Tweets by

@pharma_BI

@AVIVA1950  

at EmTech MIT 2021,  #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021

Logo of Leaders in Pharmaceutical Business Intelligence (LPBI) Group

@pharma_BI

7h

LPBI

@pharma_BI

@AVIVA1950

covered in Real Time the Virtual

@MIT

Technology Review’s flagship event, September 28-30, 2021 – #EmTechMIT 2021 EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Techno…https://lnkd.in/eFCbbwsa

Stephen J Williams

@StephenJWillia2

·

Oct 2

Promote your next #biotech #medical #conference over

@Twitter

and social media with

@Pharma_BI

Live Press Coverage https://pharmaceuticalintelligence.com/press-coverage/

@AVIVA1950

Press Coverage

Press Coverage is a Service that we offer to Biotech and Medicine, Scientific and Business Conference Organizers.   Click on these Links    Part One: The Process of Real Time Coverage usi…

pharmaceuticalintelligence.com

Stephen J Williams

@StephenJWillia2

·

Oct 2

Live Coverage #EmTechMIT 2021 – Day 2: Leading with innovation, Virtual #techreview flagship event, #AI #biothreats

@Google

@RaytheonTech

& more! https://pharmaceuticalintelligence.com/2021/09/29/emtech-mit-2021-day-2-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/… via

@pharma_BI

@AVIVA1950

EmTech MIT 2021 – Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event,…

Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 Leaders in Pharmaceutical Business Intelligence (LPBI) Group Leaders in Pharmaceutical Bus…

pharmaceuticalintelligence.com

1

1

Stephen J Williams

Retweeted 3 Tweets you were mentioned in

I will be covering this event in Real Time @pharma_BI @AVIVA1950 #event @MIT #Technology https://lnkd.in/eHVFegQp

Show all

Stephen J Williams

liked 4 Tweets you were mentioned in

I will be covering this event in Real Time @pharma_BI @AVIVA1950 #event @MIT #Technology https://lnkd.in/eHVFegQp

Stephen J Williams

@StephenJWillia2

·

Oct 2

Live Coverage Day 3: Leading with innovation, Virtual #MIT #Technology Review’s flagship event, Sept 28-30, 2021 https://pharmaceuticalintelligence.com/2021/09/30/day-3-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/… via

@pharma_BI

@pharma_BI

@AVIVA1950

#EmTechMIT

Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, …

EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 Leaders in Pharmaceutical Business Intelligence (LPBI) Group Leade…

pharmaceuticalintelligence.com

alok sinha

and

Sumant Sinha

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Sumant Sinha Founder, Chairman, Renew Power India exceeded Paris Guidelines, Government involved in Renewable energies. Faster adoption. cost of renewal energy is plummeting. Demand increased by 5%-10% in coming 3 years, In 10 years 10%-15%

Jennifer Strong

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Urho Konttori Cofounder and CTO, VarjoVR and XR headsets: True Telepresence, device will be size of goggles. In 2025 standardization of the Industry.Human communication iwll be come Teleportation

MIT Technology Review

@techreview

·

Sep 29

Replying to

@AVIVA1950

and

@Pharma_BI

Thanks for joining us again

@AVIVA1950

. We loved your tweets yesterday!

1

1

AI Bot by uCloudify.com

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Will Douglas Heaven Senior Editor for AI, MIT Technology Review presents the Panel on #AI as a Global #Disruptor

ColdQuanta

liked 4 of your Tweets

@pharma_BI @AVIVA1950 #EmTechMIT Judith Olson Head of Atomic Clock Division, ColdQuanta Next generation of #GPS local network of clock landslide alert system to use GPS, precision timing, atomic is a better clock over time satellites and vehicles rugged and portable hydrogen

Jadson C. Santos

liked 2 of your Tweets

@pharma_BI @AVIVA1950 #EmTechMIT Polls of Blockchain: many (34%) said it change the World. Few said will invest in it or will use it. Call to have more regulations Congress try to regulate the Internet may e coming Technology & Ingenuity gap robots can empower humans unfamiliar

Show all

Stephen J Williams

liked your Tweet

Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/… via @pharma_BI @AVIVA1950 #EmTechMIT @StephenJWillia2

Stephen J Williams

Retweeted your Tweet

Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/… via @pharma_BI @AVIVA1950 #EmTechMIT @StephenJWillia2

Stephen J Williams

@StephenJWillia2

·

Sep 28

@Pharma_BI

@AVIVA1950

Quote Tweet

MIT Technology Review

@techreview

 · Sep 28

This leads to successful transformation, according to @McKinsey. #EmTechMIT

Show this thread

Stephen J Williams

liked 6 of your Tweets

@pharma_BI @AVIVA1950 #EmTechMIT Aamer Baig Senior Partner, McKinsey Technology The #CLOUD Enabler and catalist (a) Strategy &amp; Management (b) Business domain adoption (c) Processes and risk postures 1. Innovate 2. Rejuvenate 3. Pioneer adoption New technologies: Blockchain



Stephen J Williams

Retweeted 5 of your Tweets

@pharma_BI @AVIVA1950 #EmTechMIT Aamer Baig Senior Partner, McKinsey Technology The #CLOUD Enabler and catalist (a) Strategy &amp; Management (b) Business domain adoption (c) Processes and risk postures 1. Innovate 2. Rejuvenate 3. Pioneer adoption New technologies: Blockchain

Show all

Fatal Exception 0E at 0137:Michael Coleman

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Aamer Baig Senior Partner, McKinsey Technology The #CLOUD Enabler and catalist (a) Strategy &amp; Management (b) Business domain adoption (c) Processes and risk postures 1. Innovate 2. Rejuvenate 3. Pioneer adoption New technologies: Blockchain

Stephen J Williams

@StephenJWillia2

·

Sep 28

@Pharma_BI

covering LIVE #EmTechMIT. Interesting set of talks on #computing #AI #machinelearning #tech in #Biotechnology

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · Sep 28

@pharma_BI @AVIVA1950 #EmTechMIT Aamer Baig Senior Partner, McKinsey Technology Cloud migration Scale and where the value comes from CIO, CFO, CEO Cloud has cost components Business opportunity that business process and business transformation



Stephen J Williams

@StephenJWillia2

·

Sep 28

@Pharma_BI

#AI #machinelearning #NLP #biomedical

Quote Tweet

Aviva Lev-Ari

@AVIVA1950

 · Sep 28

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Daniel Theobald Founder CIO Vecna Robotics Where the Optimization will come from? Supply Chain problem solving. Edge computing like Cloud computing allows to collect data Robots collect data – automated guided vehicles

uk PhD

and 4 others liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

Abhinav Sharma

and 4 others liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

Erin Underwood

liked 2 of your Tweets

@pharma_BI @AVIVA1950 #EmTechMIT Michael Casey Chief Content Officer, CoinDesk adoption of bitcoin increased during COVID, NFT – what do you own? you own the NFT it is very valuable, decentralized status mechanism NFT’s value is their scarcity

Show all

Ichimoku S₳n (Ex Nihilo Nihil Fit)

and

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Sandbox

and

Matt Skokos

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

Jadson C. Santos

and

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

Mohan

and

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

All Tweets by @pharma_BI and by @AVIVA1950 at EmTech MIT 2021,  #EmTechMIT,

Technology Review’s flagship event

September 28-30, 2021

Image
Aviva Lev- Ari, PhD, RN, Founder, 1.0 LPBI and 2.0 LPBI

e-PROCEEDINGS of this event

LPBI covered in Real Time the Virtual MIT Technology Review’s flagship event, September 28-30, 2021 – EmTech MIT 2021

  • EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

https://event.technologyreview.com/emtech-mit-2021/agenda

  • Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
  • Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
  • EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

LIST of TWEETS by

@pharma_BI and @AVIVA1950 at this event

Aviva Lev-Ari

@AVIVA1950

Sep 30

Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 https://pharmaceuticalintelligence.com/2021/09/30/day-3-leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/… via

@pharma_BI

@AVIVA1950

#EmTechMIT

Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, …

EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 Leaders in Pharmaceutical Business Intelligence (LPBI) Group Leade…

pharmaceuticalintelligence.com

Aviva Lev-Ari

@AVIVA1950

Sep 30

Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, …

EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 Leaders in Pharmaceutical Business Intelligence (LPBI) Group Leade…

pharmaceuticalintelligence.com

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT James Temple, MIT TR Green Hydrogen was a surprise the need and the interest cost is deceasing it is in our capacity to overcome Amy Nordrum innovators under 35 small satellite hand size CRISPR as Diagnostics

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Dava Newman Director, MIT Media Lab New directions Bionics and prostetics for kids 3D Printing Assists Health and Wellness. Surgery and MGH collaboration Robotics Limbs. Videos using systemic view. Co-create the vision AI and data from Satellite

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Dava Newman Director, MIT Media Lab Co-create the vision AI and data from Satellite Bridge ML and Data physics Predict crime in cities, inequality sensors in Urban environment to change behavior in Cities near Coast line floods. Buildings

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Diversity inclussivity celebrated makers, designers, iterate and mind play creatively envisioning 10 years in the future invention of the future, users, communities and communities, co-create

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Dava Newman Director, MIT Media Lab Transition from a financial crisis and the Pandemic interruption – emergence into great opportunities with societal impact. New directions Bionics and prostetics for kids 3D Printing Assists Health and Wellness

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Jesse Levinson Co-Founder CTO, Zoox Autonomous Vehicle for Urban Challenge History of Zoox, 2014 Better way to create a new type of car optimize on Drivers experience vs autonomous vehicle Symmetrical and Bi-directional, shorter car interior big

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Jesse Levinson Co-Founder CTO, Zoox Passenger different experience add premium features, car is rented for few hours only.RObotTaxi like LIFT without a driver, each ride is in the same car. Expirience is UNIQUE to Zoox

Aviva Lev-Ari

@AVIVA1950

Sep 30

@sumant_sinha

please retweet my Tweet I am PRESS at the #EmtechMIT

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Varun Sivaram American companies to assist in South East Asia in Clean energy, Book Energize America. Steel synthetic fuel from petrochemical, like solar drive cost down

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Varun Sivaram Senior Director, Clean Energy & Innovation, U.S. Department of State Clean energy transition US will leverage technologies around the Global Drive down cost for Cleaner technologies National Labs lessons to be shared technical talent

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Leah Ellis CEO and Cofounder, Sublime SystemsPatent-pending electrochemical system based on MIT research totally decarbonized cement commercially viable technology to scale cement made today

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Anthony Brower Director of Sustainable Design, Gensler 2030-2050 Building code in CA GREEN in 2045. Solar energy and scaling in residential

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Mircea Dinca Professor, MIT; Cofounder, Transaera How AC can consume 50% less energy an adds on device on top of AC unit to deal with the water cool air not cool water Technology and Policy must work together reduce energy consumption

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Meagan Mauter Associate Professor, Stanford University Automation, Precision preparation of resilient systems manage separation processing margilarity in water consumption electrify smart

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Anthony Brower Director Gensler Building geometry, low tech shift from Rectangular to Square foot print. move stairs outside the building. Roof design Green rook sun is absorbed, eliminate lighting by sensor lighting reduce energy construction

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Kate Marvel NASA’s Evaporation leads to droughts, Cold snaps like TX, cold air and Jet stream, Air quality particle level Ozon, high Probabilities based of 1988 projections of Temp getting it right for 2010 Warming is expected How bad gets

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Kate Marvel NASA’s Goddard Institute for Space Studies; Professor, Columbia University Problem Space, Physical Climate Scientist Human are causing ALL the climate change, vulcanos not responsible for warming TEMP dopping the weather Heat waves

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Christoph Noeres Head of Green Hydrogen (GH) Electrolysis process of production of GH de-carbonizing by CO2 free for green housing low cost renewable industry at scale to push forward transport supply chain Green Hydrogen industry transformation

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Leah Stokes UC Santa Barbara Clean Energy to power homes and cars, pollution is draining the Power potential. Fossil fuel infrastructure IMPEDE decrease of Temperature by 5 degrees Celcius. Let’s make Clean energy cheaper by policy incentives

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Bill McKibben Cofounder http://350.org Washington Clean Energy Incentives, Utilities are engaged, Demand from the Public, investment $50Trillion divestment by Universities from Oil related investment.

350.org: A global campaign to confront the climate crisis

We are standing up to the fossil fuel industry to stop all new coal, oil and gas projects and build clean energy future for all.

350.org

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Bill McKibben Cofounder http://350.org Climate change challenging fossil fuel energy industry. Changing is hard against Utilities and Oil interests

350.org: A global campaign to confront the climate crisis

We are standing up to the fossil fuel industry to stop all new coal, oil and gas projects and build clean energy future for all.

350.org

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Jesse Jenkins Princeton University Cleaners energies 2030 50% lower emission Presidential mandate. Cost of batteries of electric cars, cost of Wind decreased by energy policy, push from oil energy to zero emission cars, accelerate clean energy

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Sumant Sinha Founder, Chairman, Renew Power India exceeded Paris Guidelines, Government involved in Renewable energies. Faster adoption. cost of renewal energy is plummeting. Demand increased by 5%-10% in coming 3 years, In 10 years 10%-15%

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Sumant Sinha Founder, Chairman, Renew Power compromise of economic growth not favorable to all stakeholders. Intermittency regarding transmission and distribution of clean energy sources. Renewable only 15%, 2030 35%. Government GRID Management

Aviva Lev-Ari

@AVIVA1950

Sep 30

@pharma_BI

@AVIVA1950

#EmTechMIT Day 3: Powering Our World Start Now ongoint till 5PM From next-generation power grids to nuclear power and renewable energy, understanding the impact, scalability, and tradeoffs of different energy technologies is critical to powering our future

 

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Urho Konttori Cofounder and CTO, Varjo VR and XR headsets focus on Professional Medical, Design and engineering, customers: Volvo, Boeing, Toyata Human Eye Resolution is the best vs consumer grade Pilot simulation used this device training pilots.

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT st Vice President, XR Tools, Unity How much compute is enabled by the Cloud computing, glasses can be used as a controlling remove device interoperability among devices, manufacturing devices to be considered for advancement

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Marc Miskin UPenn application of microelectronic for design of robots microorganism size not visible to eye laser spot is a control function parallel design of one robot allows deployment of an army of robots like microorganisms Repair of nerves

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Janice ChenCofounder CTO, Mammoth BiosciencesOn Demand Diagnostic Tool based on CRISPR: read, detect, Protein Discovery – Meta-genomics – proteins Cas14, delivery advantages. Target proteins for diagnostics: detect DNA and RNA the exact sequence

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Jonathan Weissman Professor, MIT; Investigator, HHMI CRISPR 2.0 under DARPA Chemical and BioChem. CRISPR gene editing correct the underlining genetics, where to cut the DNA for changing the sequence Cas9 – complicated technology.

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Jonathan Weissman Professor, MIT; Investigator, HHMI Turn up and down -Silence a gene, an existing gene programmable Epigenetic memory engineering (15 month) n CRISP off Variant 1 vs CRISPR off Variant 2 only the targeted gene precision editing

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Christina Rudzinski Lincoln Laboratory, MIT Priority is both detection in advance and the vaccine capability virus detected as pathogen Actice biological weapons Nation states as adversary Lab escape virus is a possibility Lab Survelience systems

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Christina Rudzinski Lincoln Laboratory, MIT Infection progression: Pre-exposure Human transmission incubation symptoms onset illness early environmental detection population survelience Bio-signal data for detection of host’s response to infection

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Christina Rudzinski Lincoln Laboratory, MIT Reducing Biological threats. COVID19 is a Global Pandemic by a pathogen, diagnostics deployed Future pathogen infections. genetically engineered pathogens pathones evolve have been used maliciously

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Roy Azevedo Education and Training 37,000 employees 5,000 were hired during the Pandemic. Three innovation new engine work, radio frequencies Radars, cyber technology

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Roy Azevedo Simulation importance in the process of AI development, the only way to know that fidelity in the system is what bring trust to the system in Pandemic just-in-time ML applied to COVID Tests modeling Virus DNA

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Roy Azevedo Knowhow Satellite system for Weather prediction system data run through scenarios ethics applied before using AI-ML algorithm latency is not affordable, operator make decision at the edge Test & Verify Modeling & Simulation perform

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Roy Azevedo President, Raytheon Intelligence & Space High-stake environments: NSA Logistics, Cyber Satellite, Weather Storms, Deploy AI to explain the recommendation for trust into the decision making. AI is distrusted as it nears autonomy

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Ron Weiss MIT Liver vascularization dysfunction, Pancreas function by design mature Organoids Cyp3A4 – for druggability. Cancer immunotherapy will be first to benefit numeric synthetic Biology for therapeutic intervention to improve precision

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Ron Weiss MIT Professor Synthetic Biology – complexity biology: Pathways and Disease state (1) Sensing (2) Logic Processing (3) Therapeutics development. Controlling Stem cell differentiation. Programming a cell development for drug development

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Ani Kembhavi Single Purpose Model vs Multi Purpose Model AI agents, CEREBRA – Cognitive Rudiments for building AI Models – multi skills models simulators, robots, based on physical principles Multi modal AI Visual, Audio, Text

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Ani Kembhavi Allen Institute for AI Research Manager Learning Skills, Learning Concepts, Search Engine Data to teach after learning skills and concepts using richer vocabularies using Visual and Text data. Learn to interact, navigate.

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Ani Kembhavi Allen Institute for AI Research Manager Single Purpose Model vs Multi Purpose Model (1) General Models (2) Understand (3) Question and get answers.

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Virginia Smith CMU Federate Learning (FL) (1) Cross Silo [high availability] vs (2) Cross device FT [communication bottleneck] – Distributive model [Privacy] interoperability [heterogeneity}. Personalized FT: among the devices Accuracy Bias Data

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Virginia Smith CMU Assistant Professor Federated Learning beneficial – Distributed AI Learning Model. Where does the Data comes from Two canonical approaches in Federated Design: Centralized Learning vs Federated Learning – training at the Edge

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Timnit Gebru Independent Scholar experiences isolation. Labor rights and anti-discrimination rights, censoring research sounds like propaganda, outside the Tech company to impact the industry, to keep Tech companies accountable own institute on AI

Aviva Lev-Ari

@AVIVA1950

Sep 29

Happy to be covering the Conference in Real Time with Social Media and e-Proceeding

Quote Tweet

MIT Technology Review

@techreview

Sep 29

Replying to @AVIVA1950 and @Pharma_BI

Thanks for joining us again @AVIVA1950. We loved your tweets yesterday!



Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT >>> Jeff Hawkins Numenta The concept of competition, Structure of the Brain is known Goal is not Human’s Intelligent machine will act in the World Computing models can be smart nto human but helping humans in Pattern recognition Consciousness AI

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT >>> Jeff Hawkins Numenta Model of the World, learning through movement, Two elements of new modeling: (1) fastest NN (2) Sparcity learn new information Integration of these theoretical concept into companies building products

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Jeff Hawkins Cofounder and Chief Scientist, Numenta Deep Learning, stattistical techniques, no intelligence in it we know how to do that, must move to learn reference brain the structure of the world we have in the brain stored info in Brain vs AI

1

Aviva Lev-Ari

@AVIVA1950

Sep 29

@pharma_BI

@AVIVA1950

#EmTechMIT Will Douglas Heaven Senior Editor for AI, MIT Technology Review presents the Panel on #AI as a Global #Disruptor



Aviva Lev-Ari

@AVIVA1950

Sep 28

Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 https://pharmaceuticalintelligence.com/2021/09/28/leading-with-innovation-virtual-mit-technology-reviews-flagship-event-september-28-30-2021/… via

@pharma_BI

@AVIVA1950

#EmTechMIT

@StephenJWillia2

Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 Day 1: Leading with innovation, Virtual M…

pharmaceuticalintelligence.com

1

2

Aviva Lev-Ari

@AVIVA1950

Sep 28

Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021 Day 1: Leading with innovation, Virtual M…

pharmaceuticalintelligence.com

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Polls of Blockchain: many (34%) said it change the World. Few said will invest in it or will use it. Call to have more regulations Congress try to regulate the Internet may e coming Technology & Ingenuity gap robots can empower humans unfamiliar

2

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Judith Olson Head of Atomic Clock Division, ColdQuanta helium permeation Why atom make a better clock allows consistence use a lot of atoms non interacting in vacuum the future of the definition of second, utilize clock in new ways

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Judith Olson Head of Atomic Clock Division, ColdQuanta disputes on automated transactions regarding transaction announcement detection of pre-earthquake coming opticla atomic clock for sell in 3 years funding and testing are limitations, microwave

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Judith Olson Head of Atomic Clock Division, ColdQuanta Judith Olson Head of Atomic Clock Division, ColdQuanta precision timing, atomic is a better clock over time satellites vehicles rugged portable hydrogen ColdQuanta’s Fieldable Optical Clocks

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Judith Olson Head of Atomic Clock Division, ColdQuanta Next generation of #GPS local network of clock landslide alert system to use GPS, precision timing, atomic is a better clock over time satellites and vehicles rugged and portable hydrogen

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT David Wentzloff Cofounder & Co-CTO, Everactive Monitoring solutions analytics for the customers Sensors on a chip energy harvesting interface to a capacitor and a storage device. FFT on the data results shipped to customer Superior wireless tech

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT David Wentzloff Cofounder & Co-CTO, Everactive Analytics requires data and data needs to be collected renewable energy sources at the micro scale: Power supply and Demand for wireless devices Batteryless technology slack systems solution a service

 

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Aamer Baig Senior Partner, McKinsey Technology The #CLOUD Enabler and catalist (a) Strategy &amp; Management (b) Business domain adoption (c) Processes and risk postures 1. Innovate 2. Rejuvenate 3. Pioneer adoption New technologies: Blockchain

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Sara Spangelo CEO & Cofounder, Swarm Technologies IoT 4Billion new devices Global affordable 150 Satellite connectivity $5 per month subscription access to water combating drought early detection of fires from satellites ofter the devices transmit

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Adnan Mehonic Assistant Professor, University College LondonTraining an AI Model using Memistore silicon oxidefor digital memory it can be used for In memory computing, Neuromorphic Computing: Digital CMOS, Neuromorphic Computing

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Silvio Micali Founder, Algorand Governance rules for decentralized vs centralized system: Who chooses the next block? Algorand – proof of stake for financial inclusion in El Salvador atomic consumption, allowing all access Blockchain functionality

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Charles Hoskinson Space is more inclusive, diverse industry. Mongolia has bitcoin and Nigeria and Vietnam had adopted bitcoin and microfinance in Kenia and Philippines

1

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Charles Hoskinson decentralization of energy consumption, hardware with limited supply, 3rd generation systems become decentralized. Speed of Networks, base ledge proof of reserve, auction computation – hybrid model decentralized and centralized

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Charles Hoskinson What is in El Salvador for crypto currency? Cardano ? Contract system, EDA is transaction system, consensus protocol, energy consumption comes from hash for every step, representation not actual, 2015 – decentralization of energy

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

2

10

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Michael Casey Chief Content Officer, CoinDesk adoption of bitcoin increased during COVID, NFT – what do you own? you own the NFT it is very valuable, decentralized status mechanism NFT’s value is their scarcity

1

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Wendy Nather Head of Advisory CISOs,

@Cisco

Security Culture, reporting security incidence fishing testing is wrong but incentivising security awareness democratizing security because technology is being security vendors need to provide options

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT

@EmTechMIT

Wendy Nather Head of Advisory CISOs

@Cisco

mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

1

7

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT Kevin Scott CTO

@Microsoft

Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

2

3

Aviva Lev-Ari

@AVIVA1950

Sep 28

@pharma_BI

@AVIVA1950

#EmTechMIT

@EmTechMIT

ScottCTO & EVP, Technology and Research, Microsoft Seen innovations training bigger models gets better in use of #microlanguage #AI solving milestone sentiment analysis of Tweets supervised models transformer models little fine tuning

Aviva Lev-Ari

@AVIVA1950

Sep 28

Covering the event in REAL TIME with Social Media

@pharma_BI

@AVIVA1950

#EmTechMIT In one hour event will start


EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021

EmTech MIT hosted by MIT Technology Review 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Covering the event in REAL TIME with

Social Media @pharma_BI @AVIVA1950 #EmTechMIT

In attendance

Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0

AGENDA Overview

https://event.technologyreview.com/emtech-mit-2021/agenda

SPEAKERS on the AGENDA

Day 3: THURSDAY, SEPTEMBER 30

Day 3: Powering Our World (11:30 a.m. – 5:00 p.m.)

11:30 a.m .Welcome RemarksJames TempleSenior Editor for Energy, MIT Technology Review

Ensuring Energy Resilience (11:35 a.m. – 1:05 p.m.)

From next-generation power grids to nuclear power and renewable energy, understanding the impact, scalability, and tradeoffs of different energy technologies is critical to powering our future.

11:35 a.m.Transitioning toward Renewable Energy Solutions

With energy demands increasing dramatically in India, we examine the critical steps that renewable energy companies need to take to compete and continue to grow. Learn how these lessons can apply to other regions and what it will take to reliably meet regional electricity needs when it matters most, while actively transitioning toward cleaner and smarter energy choices.

Sumant Sinha Founder, Chairman & Managing Director, Renew Power

>>>India exceeded Paris Guidelines, Government involved in Renewable energies. Faster adoption. cost of renewal energy is plummeting. Demand increased by 5%-10% in coming 3 years, In 10 years 10%-15% – compromise of economic growth not favorable to all stakeholders. Intermittency regarding transmission and distribution of clean energy sources. Renewable only 15%, 2030 35%. Government GRID Management solar resource, storage cost will solve intermittency.

12:00 p.m.Cleaning Up the Power Sector

Today’s carbon-based power sources won’t safely sustain our growing electricity needs as climate change accelerates. The path forward requires decarbonizing the grid as rapidly as possible. We take a deep dive into the technologies, policies, and strategies needed to keep the lights on as rising demands and shifting climate conditions put ever greater strains on our power grids. What choices will have the greatest impact in delivering the clean energy required to run our world?

Jesse Jenkins Assistant Professor, Princeton University

>>> Cleaners energies 2030 50% lower emission Presidential mandate. Cost of batteries of electric cars, cost of Wind decreased by energy policy, push from oil energy to zero emission cars, accelerate clean energy is on the way.

Bill McKibben Cofounder & Senior Advisor, 350.org

>>> Washington Clean Energy Incentives, Utilities are engaged, Demand from the Public, investment $50Trillion divestment by Universities from Oil related investment. Climate change challenging fossil fuel energy industry. Changing is hard against Utilities and Oil interests

Leah Stokes Associate Professor, UC Santa Barbara

>>> Clean Energy to power homes and cars, pollution is draining the Power potential. FOssil fuel infrastructure IMPEDE decrease of Temperature by 5 degrees Celcius. Let’s make Clean energy cheaper by policy incentives to use and afford then deal with incease tax of fossil fuel.

Julian Brave NoisenCat Vice President, Policy & Strategy, Data for ProgressModerator

>>>

12:45 p.m.Transforming Clean Energy with Green Hydrogen

Hydrogen is energy-dense and burns cleanly, emitting no carbon dioxide. But until now, most hydrogen has been made from natural gas using a polluting and energy-intensive process. Get an early look at a transformational clean approach to producing hydrogen that has the potential to revolutionize the global energy sector. As featured in the 10 Breakthrough Technologies 2021

.Christoph Noeres Head of Green Hydrogen, thyssenkrupp Uhde Chlorine Engineers

@pharma_BI@AVIVA1950 #EmTechMIT Christoph Noeres Head of Green Hydrogen (GH) Electrolysis process of production of GH de-carbonizing by CO2 free for green housing low cost renewable industry at scale to push forward transport supply chain Green Hydrogen industry transformation

MIT Inside Track (1:05 p.m. – 1:45 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

1:05 p.m.Networking Break

1:20 p.m.Scaling Solutions for Emerging Economies

Creating scalable technology solutions in developing countries comes with its own unique constraints and opportunities. Gain insight into entrepreneurship in emerging economies including lessons in adapting existing technology and creating unique design assembly methods.

Harald Quintus Bosz CTO, Scaletech Countering Climate Change

>>> Building blocks of economic complexity

(1:45 p.m. – 3:20 p.m.)

As climate change marches on, the financial costs to businesses and nations are set to soar. Adopting climate-smart strategies will help to reduce risk while making a positive impact using the latest in green building technologies and more.

1:45 p.m. Weathering the Storm

Wildfires, heatwaves, and other extreme weather events are becoming more common and severe as the planet warms. Investigate the science behind climate change, how humans are influencing it, and what we can still do to address the rising dangers.

Kate Marvel NASA’s Goddard Institute for Space Studies; Professor, Columbia University

>>> Problem Space, Physical Climate Scientist Human are causing ALL the climate change, volcanos not responsible for warming TEMP altering the weather Heat waves, sea level rise, transfer of water from continents to oceans stronger hurricanes, tropical cyclone are stronger, increase in FIRES, Evaporation leads to droughts, Cold snaps like TX, cold air and Jet stream, Air quality particle level Ozon, high Probabilities based of 1988 projections of Temp getting it right for 2010 Warming is expected How bad gets. Climate sensitivity, cutting CO2 cutting Emission, Actions do matters, uncertainty is human behavior, sensitive climate What humans do? 5 degree Celcius is in Humans actions. 2020 – COVID Pandemic, 7% decrease in CO2 pollution caused increase in warming by clearing the sky. Avoid catastrophic effect. Positive view, under Human control are policies and effects behavior. Next year stop burn fossil fuel,

2:15 p.m.Creating Climate-Smart Buildings

The spaces where we live and work must adapt to the changing climate. Before investing in new spaces, discover how climate-smart innovations can boost our buildings’ efficiencies, including cooling, water recycling, and sustainable design.

Mircea Dinca Professor, MIT; Cofounder, Transaera

>>> AC new generation 50% more efficient than 2021 technology in AC

Meagan Mauter Associate Professor, Stanford University

>>> Automation, Precision preparation of resilient systems manage separation processing margilarity in water consumption electrify smart. Upgrading water and road infrastructure. Budget issues, achieve low carbon future. large centralized infrastructure become in adequate, build new small scale hybrid systems at the edge. Better use existing sunk costs. Water desalination manufacturing to save water and energy. Municipal treatment efficiencies next generation systems. Reuse of desalinated water. Retrofit buildings.

Anthony Brower Director of Sustainable Design, Gensler

>>> Building geometry, low tech shift from Rectangular to Square foot print. move stairs outside the building. Roof design Green rook sun is absorbed, eliminate lighting by sensor lighting reduce energy construction. 2030-2050 Building code in CA GREEN in 2045. Retrofitting buildings: this is the best 1st step.

Innovators Under 35 (2:50 p.m. – 3:20 p.m.)

2:50 p.m.Corporate Citizenship and the Risk We are not Thinking about – Presented by JPMorgan Chase

Awareness of the impending climate change challenges is growing in leadership circles, and the stakes are high. The imperative to integrate sustainability in business practices not only bolsters customer loyalty and attracts talent, it addresses climate change as an increasing risk to business as usual – worldwide.

Lori Beer Global CIO, JPMorgan Chase

2:55 p.m.Eliminating Carbon Emissions from Cement

Cement production accounts for approximately 7% of the planet’s carbon emissions. Learn how electrochemical synthesis of cement can eliminate carbon emissions for concrete production. As featured in the 2021 Innovators Under 35.

Leah Ellis CEO and Cofounder, Sublime Systems

>>> Patent-pending electrochemical system based on MIT research totally decarbonized cement commercially viable technology to scale cement made today. Green cement batch of tons of Cement not using fossil fuel.

3:10 p.m.Energy Transitions for Emerging Economies

Emerging economies require an intense amount of power. What does it take to create a scalable system that delivers reliable power as needed, where needed, and when needed? As featured in the 2021 Innovators Under 35.

Varun Sivaram Senior Director, Clean Energy & Innovation, U.S. Department of State

>>> Varun Sivaram Senior Director, Clean Energy & Innovation, U.S. Department of State Clean energy transition US will leverage technologies around the Global Drive down cost for Cleaner technologies National Labs lessons to be shared technical talent. Transportation and clean energy.

MIT Inside Track (3:20 p.m. – 3:55 p.m.)

Join the Inside Track sessions to engage more deeply with our content, speakers, and your fellow attendees during mainstage programming breaks.

3:20 p.m.Networking Break

3:30 p.m.Endless Ecosystems

Endless ecosystems is a framework for sustainable construction that combines design, digital fabrication, material development, and energy evaluation that uses 100% natural, recyclable materials. Inspired by nature, these modern materials and building practices bring the power and sustainability of the natural world to human systems.

Nic Lee Research Assistant, MIT Media Lab

Andy LippmanAssociate Director, MIT Media Lab

Turning Innovation Into Action (3:55 p.m. – 5:00 p.m.)

Research and innovation are only a few steps to achieving impactful change. Assess unique leadership approaches to chart the course for implementation from the lab to the real world.

3:55 p.m.Driving Innovation

The new era of autonomous vehicles is revolutionizing transportation. Take a deep dive into the process of changing an industry and reimagine the way we think about innovation, leadership, and design.

Jesse Levinson Co-Founder & CTO, Zoox

>>> Autonomous Vehicle for Urban Challenge Competition

History of Zoox, 2014 – Better way to create a new type of car optimize on Drivers experience vs autonomous vehicle Symmetrical and Bi-directional, shorter car, interior more space Passenger different experience add premium features, car is rented for few hours only.RObotTaxi like LIFT without a driver, each ride is in the same car. Expirience is UNIQUE to Zoox. 1/3 of Traffic is seeking for Parking this car will enable to convert Parking lots into Gardens, reduce road injuries. Congestion in Urban area requires a new vehicle. How to keep this car secure? AI driven. Zoox is not for sale. it is only for rent. so stealing, GPS knows where all Zoox are at any minute. AI ascertain safety. Passenger can stop the vehicle and can open the door and leave. TRUST is built over time. Zoox was acquired by Amazon. Amazon was attracted to Big Ideas will have Societal impact. Economic Opportunities of RoboTaxis and Societal Public good benefit.

4:25 p.m. The Future of Research and Innovation

The MIT Media Lab is the innovation center of MIT, bringing together researchers from across the globe to explore and develop new technologies that will transform the future of research as well as real-world applications. What are the issues, obstacles, and opportunities that will have the greatest impact on the world? Step with us into the lab where they lead with innovation. Dava Newman Director, MIT Media Lab

>>> Transition from a financial crisis and the Pandemic interruption – emergence into great opportunities with societal impact. New directions Bionics and prostetics for kids 3D Printing Assists Health and Wellness. Surgery and MGH collaboration Robotics Limbs. Videos using systemic view. Co-create the vision AI and data from Satellite Bridge ML and Data physics Predict crime in cities, inequality sensors in Urban environment to change behavior in Cities near Coast line floods. Buildings, manufacturing, Green and Clean. Responsibility and implementation equitable diversity challenging ideas: Art, design, Engineering, Science

4:50 p.m.Closing Remarks

Mat Honan Editor in Chief, MIT Technology Review

>>> James Temple, MIT TR Green Hydrogen was a surprise the need and the interest cost is deceasing it is in our capacity to overcome Amy Nordrum innovators under 35 small satellite hand size CRISPR as Diagnostics.